

**Genetic aspects of outcome in kidney  
transplantation:  
cytokine and thrombosis associated candidate genes  
and gene expression biomarkers**

Noora Alakulppi

Finnish Red Cross Blood Service  
and Division of Genetics,  
Department of Biological and Environmental Sciences,  
Faculty of Biosciences,  
University of Helsinki, Finland

ACADEMIC DISSERTATION

To be publicly discussed, with the permission of the Faculty of  
Biosciences, University of Helsinki, in the Nevanlinna Auditorium of the  
Finnish Red Cross Blood Service, Kivihaantie 7, Helsinki,  
on January 18th, 2008, at 12 noon.

Helsinki 2008

ACADEMIC DISSERTATIONS FROM  
THE FINNISH RED CROSS BLOOD SERVICE  
NUMBER 51

SUPERVISORS

Docent Jarmo Laine, MD, PhD  
Finnish Red Cross Blood Service  
Helsinki, Finland

Docent Jukka Partanen, PhD  
Finnish Red Cross Blood Service  
Helsinki, Finland

REVIEWERS

Docent Maija Wessman, PhD  
Folkhälsan Research Center  
Finnish Genome Center  
University of Helsinki, Finland

Docent Petri Koskinen, MD, PhD  
Department of Medicine, Division of Nephrology  
Helsinki University Central Hospital  
University of Helsinki, Finland

OPPONENT

Docent Hannu Jalanko, MD, PhD  
Hospital for Children and Adolescents  
Biomedicum Helsinki  
University of Helsinki, Finland

ISBN 978-952-5457-14-8 (print)  
ISBN 978-952-5457-15-5 (pdf)  
ISSN 1236-0341  
<http://ethesis.helsinki.fi>  
Helsinki 2008  
Yliopistopaino

# TABLE OF CONTENTS

LIST OF ORIGINAL PUBLICATIONS .....	6
ABBREVIATIONS.....	7
ABSTRACT .....	9
INTRODUCTION .....	11
REVIEW OF THE LITERATURE .....	12
1 KIDNEY TRANSPLANTATION .....	12
1.1 General aspects of kidney transplantation .....	12
1.2 Genetic aspects of end stage renal disease.....	13
1.3 Human leukocyte antigen .....	14
1.3.1 Basic features of human leukocyte antigen biology .....	14
1.3.1.1 Immunogenetics of the human leukocyte antigen system .....	14
1.3.1.2 Antigen processing and presentation .....	17
1.3.1.3 Human leukocyte antigen and T cell selection .....	18
1.3.1.4 Interaction between specific human leukocyte antigen molecules and peptides.....	19
1.3.2 Clinical histocompatibility and human leukocyte antigen matching .....	19
1.4 Complications in kidney transplantation .....	20
1.4.1 Acute rejection .....	21
1.4.1.1 Immune systems involved in rejection .....	22
1.4.1.2 Allorecognition .....	23
1.4.1.3 Tolerance.....	24
1.4.2 Delayed graft function.....	24
1.4.3 Cytomegalovirus infection .....	25
1.4.4 Vascular complications .....	25
1.5 Genes associated with acute rejection, delayed graft function, cyto- megalovirus and vascular complications .....	26
1.5.1 Cytokine genes .....	27
1.5.1.1 Tumor necrosis factor .....	29
1.5.1.2 Transforming growth factor beta 1 .....	29
1.5.1.3 Interleukin 10 .....	29
1.5.1.4 Interleukin 6 .....	30
1.5.1.5 Interferon gamma.....	30
1.5.2 Thrombosis-associated genes.....	31
1.5.2.1 Coagulation factor V.....	31
1.5.2.2 Coagulation factor II .....	31
1.5.2.3 Methylenetetrahydrofolate reductase .....	32
1.5.2.4 Protein C, tissue factor pathway inhibitor, coagulation factor XIII.....	32
1.5.3 Other genes studied in renal transplantation .....	34
1.6 Methods and biomarkers studied by these methods for diagnosing acute rejection .....	34

1.6.1 Histology .....	35
1.6.2 Enzyme-linked immunoabsorbent assay .....	36
1.6.3 Fluorescence activated cell sorting .....	37
1.6.4 Mass spectrometry .....	37
1.6.5 TaqMan real-time quantitative polymerase chain reaction .....	38
1.6.6 Microarray .....	38
2 AIMS OF THE STUDY .....	42
3 PATIENTS .....	43
4 ETHICAL PERMITS .....	43
5 METHODS .....	44
5.1 Isolation of DNA (I, II, IV) .....	44
5.2 Human leukocyte antigen typing (I) .....	44
5.3 Determination of single nucleotide polymorphisms (I, II, IV) .....	44
5.4 Isolation, quantification and validation of RNA from whole blood (III, V) .....	45
5.5 Real-time quantitative polymerase chain reaction (III, V) .....	45
5.6 Low-density array (V) .....	47
5.7 Microarray (V) .....	47
5.8 Statistical analyses (I–V) .....	48
6 RESULTS AND DISCUSSION .....	49
6.1 Acute rejection (I, IV) .....	49
6.1.1 Only a few gene polymorphisms were associated with acute rejection (I) .....	50
6.1.2 Genetic variation in thrombosis-associated or cytokine genes did not associate with AR (IV) .....	52
6.2 Genetic variation in interleukin 10 but not in other cytokine genes predisposed to CMV infection (II) .....	53
6.3 Genetic variation in thrombosis-associated or cytokine gene poly- morphism did not predispose to thrombosis (IV) .....	56
6.3.1 Thrombosis-associated or cytokine gene polymorphisms did not predispose to infarction (IV) .....	57
6.3.2 Thrombosis-associated or cytokine gene polymorphisms were not associated with graft survival .....	58
6.4 Gene expression markers showed similar time-related variance during hospital stay in control patients (III) .....	59
6.5 The expression of two genes was different in rejection patients than in control patients (III) .....	61
6.6 Rejection patients differed from non-rejection patients with regard to one gene expression marker (III) .....	63
6.7 Candidate gene expression markers did not differ between patients with subclinical rejection and control patients (V) .....	64
6.8 Gene expression markers of the low-density array were unable to identify patients with subclinical rejection (III) .....	65
6.9 A robust biomarker specific for subclinical rejection could not be identified in whole genome microarray analysis (III) .....	66

STRATEGIES FOR THE FUTURE .....	68
CONCLUSIONS .....	69
ACKNOWLEDGEMENTS .....	70
REFERENCES .....	71
ORIGINAL PUBLICATIONS .....	95

## LIST OF ORIGINAL PUBLICATIONS

This thesis consists of the following original publications, referred to in the text by Roman numerals (I–V).

- I Alakulppi NS, Kyllönen LE, Jäntti VT, Matinlauri IH, Partanen J, Salmela KT, Laine JT. Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. *Transplantation*. 2004 Nov 27;78(10): 1422–8.
- II Alakulppi NS, Kyllönen LE, Salo HM, Partanen J, Salmela KT, Laine JT. The impact of donor cytokine gene polymorphisms on the incidence of cytomegalovirus infection after kidney transplantation. *Transpl Immunol*. 2006 Nov;16(3-4):258–62.
- III Alakulppi NS, Kyllönen LE, Partanen J, Salmela KT, Laine JT. Diagnosis of acute renal allograft rejection by analyzing whole blood mRNA expression of lymphocyte marker molecules. *Transplantation*. 2007 Mar 27;83(6):791–8.
- IV Alakulppi NS, Kyllönen LE, Partanen J, Salmela KT, Laine JT. Lack of association between thrombosis associated and cytokine candidate gene polymorphisms and acute rejection or vascular complications after kidney transplantation. *Nephrol Dial Transplant*. 2007 Aug 17; [Epub ahead of print].
- V Alakulppi NS, Seikku P, Jaatinen T, Holmberg C, Laine JT. Feasibility of diagnosing subclinical renal allograft rejection in children by whole blood gene expression analysis. Submitted.

Articles I–IV are reproduced with the kind permission of their copyright holders.

## ABBREVIATIONS

ADCC	antibody-dependent cell cytotoxicity
APC	antigen-presenting cell
AR	acute rejection
CD3E	CD3e molecule, epsilon (CD3-TCR complex)
CD40LG	CD40 ligand (CD154)
CI	confidence interval
CIT	cold ischemia time
CMV	cytomegalovirus
CNF	congenital nephrotic syndrome of the Finnish type (NPHS1)
CTLA4	cytotoxic T-lymphocyte-associated protein 4
dbSNP	database of single nucleotide polymorphisms <a href="http://www.ncbi.nlm.nih.gov/SNP/">www.ncbi.nlm.nih.gov/SNP/</a>
DC	dendritic cell
DGF	delayed graft function
DN	diabetic nephropathy
DNA	deoxyribonucleic acid
DTH	delayed-type hypersensitivity
ELISA	enzyme-linked immunosorbent assay
ESRD	end stage renal disease
F2	coagulation factor II
F5	coagulation factor V
F13A1	coagulation factor XIII
FASLG	fas ligand (FL)
GZMB	granzyme B (GB)
GNLY	granulysin (Gra)
GS	graft survival
GWA	genome wide association
HLA	human leukocyte antigen
HR	hazard ratio
ICOS	inducible T cell co-stimulator
IFNG	interferon gamma
Ig	immunoglobulin
IL6	interleukin 6
IL10	interleukin 10
LD	linkage disequilibrium
LTA	lymphotoxin alpha

MALAT1	metastasis associated lung adenocarcinoma transcript 1
MHC	major histocompatibility complex
MTHFR	methylenetetrahydrofolate reductase
NK	natural killer cell
OR	odds ratio
PBL	peripheral blood leukocyte
PDCD1	programmed cell death 1 (PD-1)
PRF1	perforin (Per)
PROC	protein C
RNA	ribonucleic acid
ROC	receiver operating characteristic
RT-QPCR	real-time quantitative polymerase chain reaction
SCR	subclinical rejection
T1D	type I diabetes
T2D	type II diabetes
TFPI	tissue factor pathway inhibitor
TGFB1	transforming growth factor beta 1
TNF	tumor necrosis factor
Tx	transplantation



## ABSTRACT

Kidney transplantation (Tx) is the treatment of choice for end stage renal disease. Immunosuppressive medications are given to prevent immunological rejection of the transplant. However, immunosuppressive drugs increase e.g. the risk of infection, cancer or nephrotoxicity. A major genetic contributors to immunological acceptance of the graft are human leukocyte antigen (*HLA*) genes. Also other non-*HLA* gene polymorphisms may predict the future risk of complications before Tx, possibly enabling individualised immunotherapy.

Graft function after Tx is monitored using non-specific clinical symptoms e.g. fever and swelling of graft and laboratory markers e.g. creatine/cystatin-c measurement. Definitive diagnosis of graft rejection, however relies on an invasive core needle biopsy of the graft. In acute rejection (AR) diagnostics there is a need for an alternative to biopsy that would be an easily repeatable and simple method for regular use. Frequent surveillance of acute or subclinical rejection (SCR) may improve long-term function. This may be especially important in SCR, where by definition there are no clinical symptoms or indications from laboratory tests.

In this thesis associations between cytokine and thrombosis associated candidate genes and the outcome of kidney Tx were studied. Cytotoxic and co-stimulatory T lymphocyte molecule gene expression biomarkers that might be useful for the diagnosis of the clinical and subclinical forms of rejection were also investigated. We found that polymorphisms in the cytokine genes tumor necrosis factor (*TNF*) and interleukin 10 (*IL10*) of the recipients were associated with AR. However, the *TNF* association was not observed in a further study implying inflated odds ratios and p-values used in the power analysis of the further study based on results from first study. A *TNF* gene polymorphism of the donors was associated with delayed graft function. In addition, certain *IL10* gene polymorphisms of the donors were associated with the incidence of cytomegalovirus infection and occurrence of later infection in a subpopulation of recipients. Further, polymorphisms in genes related to the risk of thrombosis and those of certain cytokines were not associated with the occurrence of thrombosis, infarction, AR or graft survival.

In the study of biomarkers for AR, whole blood samples were prospectively collected from 50 adult kidney Tx patients. With real-time quantitative PCR (RT-QPCR) gene expression quantities of CD154 and

ICOS genes differentiated the patients with AR from those without, but not from the patients with other causes of graft dysfunction.

Biomarkers for SCR were studied in 31 paediatric kidney transplantation patients. We used RT-QPCR to quantify the gene expression of immunological candidate genes in a low-density array format. In addition, we used RT-QPCR to validate results of the microarray analysis. No gene marker differentiated patients with SCR from those without SCR. This research demonstrates the lack of robust markers among polymorphisms or biomarkers in investigated genes that could be included in routine analysis in a clinical laboratory. Even though weak associations were found, their predictive value was insufficient for use in clinical decision-making.

In genetic studies, kidney Tx can be regarded as a complex trait, i.e. several environmental and genetic factors may determine its outcome. A number of currently unknown genetic factors probably influence the results of Tx. Added complexity for assessing outcome is provided by the interplay of genetic with environmental factors.

## INTRODUCTION

The human kidneys are two bean-shaped organs situated retroperitoneally one on each side of the backbone. Each kidney consists of one to two million nephrons. A nephron has a complex structure consisting of a glomerulus, a Bowman's capsule, a proximal convoluted tubule, a loop of Henle, a distal convoluted tubule and a collecting tubule. The nephron filtrates surplus or waste molecules and ions from the blood to urine and returns useful materials back to circulation. In this manner the kidneys maintain body homeostasis. The human kidney also secretes two hormones, erythropoietin and calcitriol, and the enzyme renin which contribute to regulation of red cell development, calcium metabolism and blood volume or blood pressure (<http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/K/Kidney.html>).

The deterioration of kidney function leads to disturbance of acid-base and water-solute balance and accumulation of end products of the nitrogen metabolism. Clinical symptoms of malfunction may be e.g. urinary retention, elevated blood pressure or fever. Laboratory markers may be e.g. high creatine quantities and protein in urine. Cardio-vascular diseases and diabetes among others expose to kidney diseases <sup>1</sup>.

# REVIEW OF THE LITERATURE

## 1 KIDNEY TRANSPLANTATION

### 1.1 General aspects of kidney transplantation

Kidney Tx is the treatment of choice for end stage renal disease (ESRD). Studies comparing the quality of patients' life before and after kidney Tx have showed a better quality of life after Tx <sup>2</sup>. Even though dialysis is a treatment for terminal kidney dysfunction, it results in inferior life expectancy. It is also more expensive to society than kidney Tx <sup>3</sup>.

The first successful kidney Tx was performed in 1954 between English living identical twins <sup>4</sup>. In the 1960s, the invention of the first immunosuppressive medications, azathioprine and steroids, enabled allotransplantation between unrelated individuals. The first kidney Tx in Finland took place in 1964 <sup>5,6</sup>. Txs in Finland are performed at Helsinki University hospital with separate Tx units for adults (Kidney Transplant Unit, Department of Surgery) and children (Pediatric Nephrology and Transplantation, Hospital for Children and Adolescents). This has facilitated the adaptation of uniform treatment protocols and follow-ups of patients in a network of university clinics as well as regional and local hospitals <sup>7</sup>. Graft and patient survivals have improved with the introduction of new immunosuppressants, in particular cyclosporine at the end of the 1970s, and tacrolimus and mycophenolate mofetil in the 1990s <sup>8</sup>. In addition, various induction antibodies against lymphocyte subpopulations have augmented the treatment repertoire <sup>9</sup>. Further, novel immunosuppressants and antibodies are under development with several currently undergoing clinical trials <sup>10,11</sup>.

Graft and patient survivals in kidney Tx worldwide vary considerably according to the treatment protocol, donor source and ethnicity. The American organisation collecting Tx statistics ([ustransplant.org](http://ustransplant.org)) gives 1-year graft and patient survival rates for adult patients with a first transplant between 2003 and 2004 of 89.5% and 94.7%, respectively. The European registry, the Collaborative Transplant Study ([ctstransplant.org](http://ctstransplant.org)), in turn gives 91% and 95.5% 1-year graft and patient survival rates, respectively, for adult patients transplanted for the first time between 2003 and 2005. Graft half-life was 7.8 years in the USA for the era 1988 - 1996 and 14.2 years in Europe for the era 1985 to 2005 implying that half-life has increased during recent years <sup>12</sup> ([ctstransplant.org](http://ctstransplant.org)).

The need for kidney Tx may arise from renal failure due to e.g. chronic or acute conditions like trauma, infection or drug toxicity. Chronic renal diseases include primary kidney diseases and certain autoimmune diseases, and may be secondary to the failure of another organ. Currently, the disease most likely to lead to kidney Tx in Finland is diabetes, with type 1 diabetes (T1D) being more often the problem than type 2 diabetes (T2D) as T2D patients are more often unfit for Tx. The second most common group of diseases are the glomerulonephropathies (excluding IgA nephropathy and focal segmental glomerulosclerosis), followed by polycystic kidneys. Other causes of uraemia include tubulointerstitial and dysplastic diseases <sup>9</sup>. A special feature of paediatric kidney Tx in Finland is the large number of patients transplanted because of congenital nephrotic syndrome of the Finnish type (CNF, NPHS1), a rare autosomal recessive disease presenting with massive proteinuria at birth <sup>13,14</sup>. The disease is responsible for approximately 50% of Tx in children.

## **1.2 Genetic aspects of end stage renal disease**

Some of the kidney diseases leading to ESRD are Mendelian disorders, e.g. NPHS1, polycystic kidney disease 1 to 3, X-linked Alport syndrome, Wilm's tumor, and familial Mediterranean fever diseases (OMIM - Online Mendelian Inheritance in Man [www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM)). However, most of the diseases leading to ESRD are genetically complex and even heterogeneous, and hence their more detailed genetic dissection is still underway <sup>15-18</sup>. As diabetic nephropathy (DN) has attracted more studies than any other ESRD, DN genetics is briefly reviewed next.

DN accounts for 40% of ESRD in the Western world. Familial clustering of DN and ethnical variation have been observed, both in T1D and T2D, indicating genetic factors in the development of the disease. A large study on nearly 26000 incident US dialysis patients from more than 450 dialysis clinics has analyzed the family history of ESRD <sup>19</sup>. Independent risk factors for a family history of ESRD in first- or second degree relatives included earlier age at ESRD onset, female gender, black ethnicity, and diabetes-associated nephropathy.

Molecular genetic studies published on DN involve family-based linkage and association studies or association analysis in a case-control study design. Linkage studies on families have either analyzed a restricted chromosomal region using a few polymorphic microsatellite markers <sup>20</sup> or the whole genome using at least 900 microsatellite markers relatively

uniformly distributed throughout the genome <sup>21</sup>. SNPs are commonly used in association analysis nowadays.

Genome-wide linkage studies on sibling pairs have identified several chromosomal regions that may harbour susceptibility genes/variants for DN. Chromosome 3q13-q25 has been indicated in DN in T2D African Americans <sup>22</sup> and in T1D DN in Caucasian families <sup>20,21</sup>, and it has been reported that adiponectin gene on 3q is a likely susceptibility gene for DN in French and Danish families <sup>23</sup>. A large region on chromosome 7q has been indicated in DN, predominantly in T2D, in several populations of different ethnic origin. Chromosome 18q22-q23 region has also evolved in T2D DN in several reports on populations of different ethnic origin <sup>22,24,25</sup>.

Some candidate genes studied code components of the renin-angiotensin system, e.g. angiotensin I converting enzyme 2 <sup>26</sup>, lipid metabolism, e.g. apolipoprotein E <sup>27</sup>, and membrane proteins such as xylosyltransferase I <sup>28</sup>, nitric oxide synthase 3 <sup>29</sup>, and superoxide dismutase 2 <sup>30,31</sup>. Currently, at least one genome wide association (GWA) study "Genetics of Kidneys in Diabetes (GoKinD)" (search at [www.jdrf.org](http://www.jdrf.org)) is being conducted. New genetic factors in DN may open the path to new molecular targets for drug development and more accurate diagnosis of DN, ultimately perhaps reducing the incidence of DN leading to ESRD <sup>32</sup>.

## **1.3 Human leukocyte antigen**

### **1.3.1 Basic features of human leukocyte antigen biology**

#### **1.3.1.1 Immunogenetics of the human leukocyte antigen system**

The major histocompatibility complex (MHC) in the human race is HLA. The *HLA* complex on chromosome 6p21.3 contains more than 200 genes, of which more than 40 encode the HLA antigens (Fig. 1). In fact, all the known *HLA* genes are located within the MHC. The remaining 150 genes or so in the MHC are not evolutionarily related to the *HLA* genes, although some are involved in HLA function, in particular to the processing of the peptide antigens, while some others have immunological functions, e.g. related to complement activation. Finally, many appear not to be related to the immune response at all <sup>33</sup>.




Figure 1. Location and Organization of the *HLA* Complex on Chromosome 6. BF denotes complement factor B; C2 complement component 2; C21B cytochrome P-450, subfamily XXI; C4A and C4B are complement components 4A and 4B, respectively; HFE hemochromatosis; HSP heat-shock protein; LMP large multifunctional protease; LTA and LTB lymphotoxins A and B, respectively; MICA and MICB major-histocompatibility-complex class I chain genes A and B, respectively; P450 cytochrome P-450; PSMB8 and PSMB9 proteasome  $\beta$  8 and 9, respectively; TAP1 and TAP2 transporter associated with antigen processing 1 and 2, respectively; TAPBP TAP-binding protein (tapasin); TNF- $\alpha$  tumor necrosis factor; and HSPA1A, HSPA1B, and HSPA1L heat-shock protein 1A A-type, heat-shock protein 1A B-type, and heat-shock protein 1A-like, respectively. Copyright © 2000 Massachusetts Medical Society. All rights reserved <sup>34</sup>.

The *HLA* genes are often divided into two major classes. Class I includes in particular the classical Tx antigens HLA A, B and Cw, and class II the HLA DR, DQ and DP. These molecules are functionally and structurally similar (Fig. 2), although they do have certain important differences. Class III is a heterogeneous collection of genes where a few families dominate. These include genes of the immunoglobulin superfamily members as well as those involved in the activation cascades of the complement system, hormonal synthesis, inflammation and cell stress, and extracellular matrix organisation. The most of the remaining loci are mainly involved in more basic biological functions with no immediate connection in the immune system <sup>35</sup>.




Figure 2. Structure of HLA Class I and II Molecules.  $\beta2m$  denotes beta2-microglobulin, TM transmembrane region. Copyright © 2000 Massachusetts Medical Society. All rights reserved <sup>34</sup>.

The  $\alpha$  chains of the HLA class I molecules are encoded by the *HLA* linked genes, whereas the  $\beta$  chain is encoded by the  $\beta2$ -microglobulin gene located on chromosome 15q21-q22. The  $\alpha$  chains have five functional domains: two domains ( $\alpha1$  and  $\alpha2$ ) together form the functionally crucial peptide binding groove, an immunoglobulin-like domain ( $\alpha3$ ), the transmembrane region, and the cytoplasmic tail (Fig. 2).

The class II molecules are also formed of two chains, but here both chains ( $\alpha$  and  $\beta$ ) are encoded by genes located in the *HLA* class II region. Each of them has four domains, which are similar to those of class I, except that there is only one peptide-binding domain in each chain ( $\alpha1$  or  $\beta1$ ); however, these two domains form a similar type of functionally important peptide binding groove (Fig. 2).

The *HLA* genes show the highest known quantity of classical, allelic genetic variation. The most polymorphic ones are *HLA-A* with over 500 alleles, *HLA-B* with over 800 alleles, *HLA-C* with over 300 alleles, and *HLA-DRB1* with over 500 alleles ([www.ebi.ac.uk/imgt/hla/stats.html](http://www.ebi.ac.uk/imgt/hla/stats.html)). There is also strong linkage disequilibrium (LD) between the *HLA* genes, in particular between the *B* and *Cw* alleles, and *DRB1* and *DQB1* alleles <sup>36,37</sup>. In other words, certain allelic combinations appear together more frequently than expected from their individual frequencies. Extended



haplotypes in the *HLA* region are conserved in many populations, e.g. haplotype *HLA-A1-B8-DR3-DQ2* is very common in many Northern European populations <sup>38,39</sup>. It is currently not established whether the LD results from some evolutionary advantage of certain allelic combination, recent population mixings, or missing recombination sites in some haplotypes.

Most human cells express the HLA A and B, and apparently HLA Cw, molecules, but their relative quantities vary between tissues. Only specific immune cells like B cells, activated T cells, macrophages, dendritic cells, and thymic epithelial cells express HLA class II molecules. However, interferon gamma (IFNG) can induce other types of cells to express the *HLA* class II genes. Basically, the HLA class I and II molecules share the same function: to present peptides to T lymphocytes. This presentation is an essential requirement for the activation of the adaptive immune response <sup>34</sup>.

#### 1.3.1.2 Antigen processing and presentation

A special molecule, ubiquitin, marks intracellular proteins that are no more needed for disassembly. Chaperones make marked proteins available to a proteasome degradation process where they are digested into peptides of variable length. Peptides are also produced in endocytic vesicles where extracellular proteins are digested by lysosomes and proteolytic enzymes <sup>40</sup>.

In addition to foreign proteins, the proteasomes also digest self-proteins, the resulting peptides being picked up by transporters associated with antigen processing (TAPs). TAP1 and TAP2 genes encode TAP proteins. TAPs form channels through the endoplasmic reticulum (ER) and peptides move via these and bind to class I molecules. The class I molecules have been assembled from  $\alpha$  chains and  $\beta_2m$  in ER with the help of chaperones like TAP-binding protein (TAPBP) and others. After binding to the suitable peptide, the class I molecule moves to the cell surface where it is displayed <sup>41</sup>.

Class II molecules are manufactured in the same way as class I molecules up until the class II molecule peptide binding in cytoplasm. Before peptide binding, the invariant chain binds to the peptide-binding groove. In the cytoplasm the class II molecules intersect with endosomes. Proteasomes, with the help of the HLA-DM molecule, cut the invariant chain and exogenous peptide binds to the groove. This complex is exported to the surface of the cell <sup>42</sup>.

In general, the class I molecules present peptides from endogenous sources and class II molecules from exogenous sources. On an uninfected cell surface, the HLA molecules bind hundreds of thousands of self-peptides. Antigen-presenting cells (APCs) express HLA-peptide complexes, which T-cells bind and recognize as self or non-self in a process described in the following sections <sup>34</sup>.

### 1.3.1.3 Human leukocyte antigen and T cell selection

T cells mature in thymus from lymphocyte progenitors. Immature double-positive T cells interact with their T cell receptor (TCR), as well as CD4 and CD8 coreceptors to HLA molecules. In the selection process if TCR binds to HLA class I, the T cell starts to down-regulate CD4 receptors and up-regulate CD8 receptors, and if TCR binds to HLA class II, the T cell starts to down-regulate CD8 and up-regulate CD4 <sup>43,44</sup> (Fig. 3).




Figure 3. Mature CD4 and CD8 positive T cells make contact with TCR and CD4 or CD8 molecules to an APCs HLA class II and class I molecules representing peptide, respectively. TCR denotes T cell receptor; HLA human leukocyte antigen; APC antigen presenting cell.

During T cell maturation in the thymic cortex T cells encounter HLA molecules. T cells that are unable to recognize the self-HLA molecules will die by apoptosis. In the thymic medulla, T cells with strong binding to self-peptides presenting HLA molecules undergo apoptosis. On the periphery, T cell binding to HLA class I molecules with a recognized ligand leads to T cell maturation to a CD8 cytotoxic killer T cell while binding to HLA class II molecules results in maturation to a CD4 helper T cell. Maturation activates T cells to produce INF $\gamma$  and other cytokines, and these cytokines enhance immune response by increasing the expression of HLA class I and II molecules <sup>45</sup>.

#### 1.3.1.4 Interaction between specific human leukocyte antigen molecules and peptides

Only a few amino acids of each peptide bind directly to the peptide binding groove of HLA. These interactions have been described in detail by crystallographic studies <sup>46,47</sup>. One *HLA* allele has the ability to bind many different peptides if they all share certain critical amino acids at particular positions, that is, they fulfil the criteria for the peptide binding motif. The amino acids that form the critical pockets of the peptide binding groove and thus determine the peptides able to bind therein, show a high quantity of genetic variation between *HLA* alleles. Hence, different *HLA* alleles bind and present to the immune response different sets of peptides. Although the peptide binding motif gives the general outline of peptides bound by each of the *HLA* alleles, the requirements are not absolute. One *HLA* allele can therefore bind thousands of different peptides <sup>48</sup> (Fig. 4).




Figure 4. A TCR recognized HLA-peptide complex. TCR denotes T cell receptor, HLA human leukocyte antigen.

*HLA* is currently the most important known genetic factor influencing the outcome of kidney Tx. In the next sections, aspects of HLA biology and matching in kidney Tx are covered.

### 1.3.2 Clinical histocompatibility and human leukocyte antigen matching

Successful kidney Tx requires, in addition to special surgical skills, careful immunogenetic matching between the donor and recipients. In many centres worldwide, Tx is only considered if (i) the recipient and donor are blood group ABO matched, (ii) the recipient has not developed prior antibodies against the donors HLA antigens (a negative cross-match), and (iii) there is sufficient *HLA-A*, *-B* and *-DR* similarity between the recipient and the donor <sup>49</sup>.

*HLA* matching for kidney Tx has two main aims. First, a good immunological histocompatibility between the donor and recipient diminishes immune activation against the graft. Second, emergence of antibodies against foreign *HLA* antigens of the graft is potentially harmful for the long-term graft survival (GS), and their emergence is certainly harmful if the recipient undergoes retransplantation. In other words, preformed antibodies, or a positive cross-match before Tx, may lead to acute or hyperacute rejection and deterioration of the graft. Long-term humoral immunity against the graft promotes chronic rejection and shortened GS <sup>50</sup>. The detection of anti-*HLA* antibodies is discussed in the section on methods for AR diagnosis.

Foreign *HLA* antigens promote cellular immunity. The cellular response can be divided into direct allorecognition, primarily by cytotoxic CD8 T cells, and indirect allorecognition by effector/helper CD4 T lymphocytes.

Worldwide there are several *HLA* matching protocols for kidney Tx. Centres may match for all *HLA*-A, -B, and -DR antigens, or some mismatching in *HLA*-A, -B, and -DR antigens, and either broad or split antigens can be tolerated. There are programs for acceptable and unacceptable mismatches for highly sensitized Tx candidates, DR-only matching, cross-reacting groups of antigen (CREG) matching, structurally based matching, amino acid residue mismatching, and *HLA* Matchmaker program matching <sup>51</sup>. In Finland, an acceptable *HLA* match involves the sharing of at least two 'broad' antigens in the *HLA*-A, and *HLA*-B genes, and one antigen in *HLA*-DR <sup>6</sup>.

Other essential factors affecting the outcome of Tx include the quality of the donor kidney, donor age, cold ischemia time, and the experience of the Tx team <sup>51</sup>. The Collaborative Transplant Study (CTS) reports that *HLA* mismatch worsened GS independently of other known factors influencing GS ([www.ctstransplant.org/](http://www.ctstransplant.org/)). Good *HLA* matching also significantly improves GS in Finnish kidney Tx <sup>52</sup>.

## **1.4 Complications in kidney transplantation**

Complications experienced by transplant recipients include AR, delayed graft function, cytomegalovirus infection, and/or vascular complications, and these are reviewed in the following sections. Other significant adverse effects (first year incidences in specific studies in parentheses) include BK-virus nephropathy (8% <sup>53</sup>) and other microbe infections, chronic rejection (4% <sup>54</sup>), post-transplant lymphoproliferative disease (1% <sup>55</sup>) and other cancers, and there are common minor problems, e.g.

cosmetic issues and mild gastrointestinal complications. These are not reviewed as they are beyond the focus of this thesis.

### **1.4.1 Acute rejection**

Rejection is an immune response to an allogeneic graft. Immunosuppressive medication is given to prevent rejection in an alloTx. A kidney Tx patient experiencing an AR episode may present with fever, chills, night sweats, myalgias, and tenderness over the allograft, oliguria and hypertension. Laboratory tests may indicate increased creatinine or a decrease in glomerular filtration rate. An ultrasound scan may reveal a swollen kidney and delayed and decreased blood flow, among other functional parameters <sup>56</sup>. These, with or without biopsy findings, usually lead to suspicion of AR. Histology and other tests in use and in development are reviewed in the section 1.6. AR is treated with steroids, or in steroid-resistant rejection with antibodies to T cells, among others. Rejection episode length and response to therapy determine the resulting graft damage, which may only be partly reversible. Permanent damage may lead to long-term deterioration of graft function. It is important to recognise patients with high rejection risk and diagnose rejection early to limit damage to the graft and improve the Tx prognosis.

Most AR episodes occur in the first three months after Tx. AR occurring later is often suspected to be related to non-compliance. However, the incidence of AR has decreased with the evolution of medical care. This has made studies in cohorts difficult, because the incidence of AR is often as low as 10 to 15%. According to [ustransplant.org](http://ustransplant.org), the incidence of AR has continually decreased from 1996 through 2004, with respective annual incidences of 51%, 29%, 21%, 19%, 17%, 17%, 15%, 13% and 11%. However, long-term GS for the patients with AR has not increased <sup>57</sup>. Future studies should probably use other endpoints to predict outcome, such as serum creatinine or glomerular filtration rates. In addition, the decreasing AR incidence has improved short-term, but not long-term, allograft survival. Factors associated with late allograft loss, such as calcineurin inhibitor toxicity, chronic rejection, and BK virus nephropathy, may provide better predictors of long-term allograft loss than AR <sup>58</sup>.

### 1.4.1.1 Immune systems involved in rejection

AR results from the innate and acquired allogeneic responses to transplanted graft. These responses follow each other in sequence, in three processes: 1) naïve host T cells recognise alloantigens, 2) alloreactive T cells are activated and expand, 3) target cell destruction takes place in an effector phase (Fig. 5) <sup>59</sup>. Alloantigens can be divided into two




Figure 5. Effector mechanisms responsible for the rejection of combined class I and class II MHC-mismatched allografts. In the direct pathway, host CD4 T cells recognize intact MHC molecules on donor dendritic cell (DC) (stained red). In the indirect pathway, recipient DC (stained blue) engulf and process donor MHC molecules before donor MHC molecules present themselves as MHC-derived allopeptides to host CD4 T cells. CD8 T cells that recognize donor MHC class I molecules will receive help from activated alloreactive CD4 T cells. The effector phase of rejection (depicted around a tubule within a kidney graft) involves: (a) CD8 and CD4 T cell cytotoxicity with the perforin/granzyme and Fas/FasL pathway, respectively; (b) CD4 and CD8 derived IFNG production and delayed-type hypersensitivity, where macrophages release toxic molecules, such as NO, TNF, and oxygen species; (c) antibodies reactive to donor MHC molecules, which will mediate complement activation or antibody-dependent cell-mediated cytotoxicity. The cells and pathways not involved in rejection are shown in grey. Copyright © 2002 Lippincott Williams & Wilkins. All rights reserved <sup>59</sup>.

classes: foreign MHC and minor alloantigens. The above discussed *HLA* matching attempts to lessen the MHC differences between the donor and recipient <sup>60</sup>. Even though full *HLA* matching were to be achieved e.g. in sibling Tx, minor alloantigen allopeptides would still result in a degree of immunoactivation as they are presented by shared donor and recipient MHC molecules <sup>61</sup>. Allopeptides derive from differences between donor and recipient proteins, e.g. male antigen in sex-mismatched Tx or proteins having amino-acid differences, or di-allelic polymorphisms in coding or controlling sequences <sup>62,63</sup>.

#### 1.4.1.2 Allorecognition

In direct allorecognition the TCR on CD8 T cells of the recipient recognize the donor's foreign HLA class I molecules directly on the cell surface. The recognition takes place in lymph nodes and spleen, where naïve alloreactive T cells contact donor APCs. Transplantation surgery is associated with ischemia/reperfusion injury which activates donor APCs to migrate from allograft to recipient lymphoid tissues <sup>64</sup>. In the indirect allorecognition recipient APC cells engulf donor HLA I and II molecules, digest them into peptides and present them via recipient HLA II molecules to the recipient's CD4 T lymphocytes. Recipient DCs circulate to the transplanted graft attracted by the chemokines and increased graft endothelial cell adhesion molecule expression. Recipient DCs circulate back to spleen and lymph nodes to prime naïve T cells <sup>65</sup>. In addition to the signal from the HLA-TCR complex, other co-signals are needed for the immune activation, in particular co-stimulatory molecules e.g. in DCs B7, CD40 and OX40 ligand and their receptors, and in T cells CD28, CTLA4, CD40LG (CD154) and OX40. Binding of these molecules triggers intracellular pathways involving IL2 secretion and activation of transcription factors such as NFκB, which activates genes expressing chemokines and cytokines <sup>66</sup>.

CD4 T cells secrete cytokines according to their differentiation into Th1 and Th2 cells. The major cytokines of Th1 cells are IFNG and IL2, which activate CD8 T cells and themselves by the expression of Fas ligand (FASLG) to cytotoxicity. Th2 cells mainly secrete IL4, IL5, IL9, IL10 and IL13, which activate eosinophils <sup>67</sup>.

Alloreactive T cell cytotoxicity is mainly mediated by perforin/granzyme and the Fas/FASLG system, leading to target cell apoptosis <sup>68</sup>. In the tight junction between cells, CTL makes contact with donor MHC molecule and cytotoxic granules fuse to the target membrane. Granule molecules trigger caspase production, which leads to apoptosis <sup>69</sup>.

B cells produce alloantibodies, which internalize foreign HLA molecules bound by their immunoglobulin (Ig). Foreign HLA molecules are cleaved into peptides which are presented by B cells' own MHC class II molecules to CD4 T cells in order to obtain signals enhancing B cell alloantibody production <sup>70</sup>. Alloantibodies binding to cells of the graft may activate the complement system, and subsequently graft-infiltrating immune cells like macrophages, neutrophils and eosinophils <sup>71</sup>. In addition, natural killer (NK) cell binding to Ig molecules initiates perforin/granzyme-mediated NK cytotoxicity, otherwise specified as antibody-dependent cell cytotoxicity (ADCC) <sup>72</sup>.

Th1 cell mediated delayed-type hypersensitivity (DTH) appears as tissue swelling and induration, where T cells, macrophages and neutrophils induce vascular permeability and inflammatory infiltrate. Antigen-specific Th1 cells release IFNG and TNF, which trigger the macrophage production of nitric oxide (NO) and oxygen intermediates. NO elicits cytotoxicity, vasodilation and edema. TNF induces apoptosis and necrosis through caspase activation. These activations lead to DTH mediated allograft rejection <sup>73</sup>.

#### 1.4.1.3 Tolerance

The ultimate aim in the prevention of AR with immunosuppression is to induce immunological tolerance between the recipient and graft. Tolerance induction is complex. It can be relatively easily induced in mouse, rat, pig and primate models of transplantation e.g. by blockade of immunological co-signals <sup>74</sup>. However, in clinical transplantation tolerance induction remains an elusive goal that seems impossible to reach with current immunosuppressive protocols. The use of cyclosporine may lead to either beneficial or adverse interaction depending on the balance between the efficacy of the co-stimulatory signal blockade and the stringency of the alloimmune response <sup>75</sup>. Tolerance induction is currently one of the main goals in transplantation research <sup>76,77</sup>.

### 1.4.2 Delayed graft function

The recipient usually starts secreting urine within the first day after kidney Tx and will no longer need dialysis. If not, the situation is called DGF. DGF is not a well-defined entity but is usually a centre dependent definition. The definition for DGF in Finland is from Halloran et al. <sup>78</sup>, i.e.



plasma creatinine concentration higher than 500  $\mu\text{mol/L}$  throughout the first post-transplant week, or need for more than one dialysis session in the first week, or oliguria  $<1\text{L}/24\text{hr}$  lasting more than two days <sup>79</sup>. The incidence of DGF varies with different factors in the donor and recipient, and in the transplant procedure <sup>80</sup>. Major factors predisposing to DGF are long cold ischemia time (CIT), high donor age, female kidney to male recipient, and high creatinine quantities in the donor <sup>81</sup>. GS is reported to be approximately 10% lower with DGF <sup>82</sup>. This fact has led to efforts to shorten CIT and to find novel drugs for diminishing the ischemia-reperfusion injury <sup>83,84</sup>.

### **1.4.3 Cytomegalovirus infection**

Cytomegalovirus (CMV) is a betaherpesvirus with linear double-stranded DNA genome. CMV infection is usually mild and subclinical, and stays as latent after infection. However, immunosuppressive medication predisposes to infections and re-activation of microbes and viruses. CMV infection occurs in 25 - 60 % of kidney graft recipients, depending on the serological status of the recipient and donor, and on prophylactic treatment. CMV serologically negative recipients (R-) who receive a serologically positive donor (D+) organ have the highest risk. These recipients often receive prophylaxis 3 - 6 months post-Tx <sup>85,86</sup>. New antiviral prophylactic treatments have reduced the risk for CMV infection considerably. CMV infection is commonly diagnosed using antigenaemia test or PCR. CMV prophylaxis reduces the one-year post-Tx incidence of AR in R-/D+ groups from 32.4% to 26.3% <sup>86</sup>. CMV disease during the first 100 days after Tx is associated with 71% GS, compared to 86% GS without CMV <sup>87</sup>.

### **1.4.4 Vascular complications**

Kidney Tx involves suture and catheterization of veins and urinary bladder. These procedures increase the risk of thrombosis (the formation, development or presence of a blood clot) immediately after operation. Recipient factors such as age, immobility, and primary disease influence the long-term risk of thrombosis and infarction. Recipient death with a functioning graft is mainly due to vascular complications, e.g. myocardial and cerebral infarctions <sup>88-91</sup>. Vascular AR may also promote microvascular thromboses, which may lead to graft loss <sup>92</sup>. In addition,

renal artery- or vein thrombosis due to surgical complications or factor V Leiden mutation may lead to immediate graft loss <sup>93,94</sup>.

## **1.5 Genes associated with acute rejection, delayed graft function, cytomegalovirus and vascular complications**

Several gene polymorphisms have been studied for their potential to predict Tx outcome (reviewed in several articles <sup>95-100</sup>). So far, these studies have been candidate gene studies on solid organ Tx, although GWA studies are underway (reviewed in later section). After the completion of human genome sequence <sup>101</sup> the International HapMap consortium has made available for everyone studying the human genome over three million SNPs validated in several populations <sup>102,103</sup>. The HapMap internet database includes also the information of LD between SNPs in same chromosome (hapmap.org). This LD can be used to choose tag SNPs which represent all the SNPs in LD with tag SNP for genotyping entire genes. In the HapMap CEU samples represent adequately basis for tag SNP selection in Finnish individuals <sup>104</sup>. In addition, tag SNPs are used among others in the genotyping platforms for GWA studies.

A good genetic association study is designed to include a sufficient number of samples, implemented to collect reliable phenotypic data, perform genotyping rigorously, and interpret results correctly <sup>105</sup>. Solid organ Tx candidate gene studies are founded on the immunological basis of Tx. Cytokines, chemokines, the receptors of mononuclear blood cells and other related genes have been screened for possible genetic variations associated with the outcome. The results from these studies have been mostly contradictory or non-conclusive due to their small size. The small patient number in these genetic studies has led to various problems, including sensitivity to variability in the patient and donor characteristics, and analysis methods. In addition, the non-consistent nomenclature of gene polymorphisms makes the comparison of studies difficult. The refSNP (rs) numbers, the standard nomenclature for gene polymorphisms from the database of single nucleotide polymorphisms (dbSNP), or Human genome variation society (HGVS) mutation nomenclature recommendations are not commonly used. Currently there is not a single gene outside the *HLA* and *ABO* blood groups that is commonly accepted to be of importance in kidney Tx <sup>106</sup>. However, comprehensive prospective studies are yet to come.

Genetic epidemiology is a term that indicates a combination of the old formal epidemiology (variables changing during an individual person's

life-time) and new emerging genetic variation typing and analysis methods (variables not changing during an individual person's life-time). Traditional epidemiology follows strict guidelines when reporting associations between environmental factors and outcomes, e.g. diseases. However, even with extremely detailed studies not everything can be taken into account as a risk factor, or measured variables are confounding, intervening, suppressing or interacting without an acknowledgement of this. Adding this to the genetic diversity, which is not limited to SNPs, several factors can influence the outcome <sup>107</sup>. Thus, many published articles may report false-positive or false-negative results <sup>108</sup>.

### **1.5.1 Cytokine genes**

Cytokines can be divided into subgroups of interleukins, interferons and miscellaneous hematopoietins. Since the launch of the HapMap project, several thousands of gene polymorphisms have been found in genes encoding cytokines. Some of these may, or have been shown to, have an effect on gene function or its expression quantities where certain allele/genotype/haplotype is associated with decreased or increased gene expression compared to the other variant. The mechanisms of these mediation effects are not usually known <sup>109</sup>. The published studies still mainly include only a single or a few polymorphisms per cytokine gene, and haplotype analyses are rare. All the cytokine genes and polymorphisms studied in this thesis are listed in table 1 which also denotes the primary source and effect of each cytokine. Relevant studies to this thesis are discussed in more detail in Results and Discussion.

Table 1. Summary of findings in the current literature demonstrating association or lack of association for each described genetic variation on graft outcome (DGF, AR, GS or patient survival).

<b>Gene polymorphism</b>	<b>dbSNP rs number</b>	<b>Allele function</b>	<b>Primary source</b>	<b>Effect</b>	<b>Association</b>	<b>Citation</b> <b>No association</b>
TNF G(-308)A	rs1800629	-308A: Transcription factor sensitivity, increases TNF transcription <sup>110,111</sup>	Macrophage, natural killer cell, T cell	Proinflammatory, local inflammation, endothelial activation	96,112-123	98,100,124-133, donor: 112,119,131,134-136
TGFB1 T(+869)C and C(+915)G	rs1982073 rs1800471	T(+869)C: Cellular TGFB1 transport, C(+915)G: Structure enzyme cleavage site <sup>137</sup> . Haplotype +869T +915C: Increased production of TGFB1 <sup>138</sup>	Chondrocyte, monocyte, T cell	Anti-inflammatory, immunosuppressive, profibrogenic, inhibits cell growth	100,118,119,121,122, 128,139, donor: 118,122,123,131,136	98,113,117,124,127,130-132, donor: 119,134,135
IL10 G(-1082)A	rs1800896	-1082G: Transcription factor binding site, increased IL10 production <sup>140</sup>	T cell, macrophages	Prohumoral, anti-inflammatory, macrophage suppressant	98,112,119,121-123, 125,128,130,139	96,100,113,117,124,126,127,129, 131-134,141-143, donor: 112,119,122,131, 134-136,143
IL10 C(-819)T and C(-592)A	rs1800871 rs1800872	Haplotype GCC: Increased IL10 production <sup>144</sup>			119,121,122,128,131,139, donor: 119	117,124,126,127,129,130,132, 142,143, donor: 122,131,135,136,143
IL6 G(-174)C	rs1800795	-174C: Negative regulatory domain, decreased IL6 production <sup>145</sup>	T cell, macrophage, endothelial cell	Procellular and humoral, acute phase protein production, fever	96,115,122,127, donor: 123,131,135	98,119,121,126,128,130-132, 135,136,143, donor: 119,122,143
IFNG T(+874)A	rs2430561	+874T: NFKB binding site, increased IFNG production <sup>146</sup>	T cell, natural killer cell	Proinflammatory, procellular	121,128, donor: 123,136	96,98,119,127,130-133, donor: 119,131

#### 1.5.1.1 Tumor necrosis factor

The most studied cytokine is TNF, mainly known for its devastating effects on sepsis leading to massive inflammatory reactions. TNF causes pro-inflammatory responses in response to several immunological challenges. Systemic TNF causes e.g. fever, hypotension, and shock <sup>147</sup>. TNF is also involved in the AR cascade <sup>148</sup>. The *TNF* gene lies on 6p21.3 in the region of MHC class III and is in LD with classical *HLA* genes <sup>149</sup>. The *TNF* gene is 2778 bases long and encodes a protein of 233 amino acids. The most studied polymorphism in the *TNF* gene is the G(-308)A promoter polymorphism that influences the expression of TNF protein <sup>111</sup>. The -308A allele associated with high cytokine expression is found in the ancestral *HLA-A1-B8-DR3* haplotype which confers susceptibility to many autoimmune diseases <sup>150</sup>. The G(-308)A polymorphism has been found to associate with the outcome of kidney Tx, although results are contradictory (Table 1).

#### 1.5.1.2 Transforming growth factor beta 1

Transforming growth factor beta 1 (TGFB1) regulates proliferation and differentiation of many cell types. In the immune system TGFB1 affects many cell types, e.g. T cell survival, proliferation, Th differentiation and effector functions <sup>151</sup>. The *TGFB1* gene lies in 19q13.2, is 23402 bases long and encodes a protein of 390 amino acids. In kidney Tx TGFB1 is known as fibrogenetic factor, whose increased expression has been associated with chronic rejection <sup>152,153</sup>. In addition, a significant association between *TGFB1* gene and graft and patient survival has been reported <sup>154</sup>. Polymorphisms in the exon 1 of the *TGFB1* gene codons 10T/C and 25C/G have been associated with the outcome of kidney Tx in many studies. Again, however, there are also many studies that have not found the association (Table 1).

#### 1.5.1.3 Interleukin 10

IL10 promotes the Th2-type immune response leading to antibody production. The effects of IL10 are generally thought to be anti-inflammatory, and to suppress the Th1-type immune response. The *IL10* gene lies in 1q32.2, is 4892 bases long and encodes a protein of 178 amino acids. There are several polymorphisms in the promoter region of *IL10*. However, the effects of these on IL10 production remain

unclear. The -1082G allele has been associated with a higher expression quantity *in vitro* and *in vivo* <sup>140</sup>. In another study, the -1082A allele was reported to confer a two-fold increase in the transcriptional activity of the *IL10* promoter compared to the G allele <sup>155</sup>.

The conflicting results of the *in vitro* and *in vivo* studies of the *IL10* polymorphisms are reflected in the clinical studies of the role of the cytokine in the development of AR <sup>140</sup>. While *IL10* polymorphisms have been reported to affect the outcome of kidney Tx in several studies, there are many reports that have been unable to detect the influence of *IL10* (Table 1).

#### 1.5.1.4 Interleukin 6

IL6 regulates many aspects of the immune response, e.g. T cell differentiation <sup>156</sup>. The IL6 quantities increase in the incidence of inflammation, tissue damage, hypoxia, or infection <sup>157</sup>. The *IL6* gene lies in 7p15.3, is 6113 bases long and encodes a protein of 212 amino acids. The *IL6* promoter haplotype regulates the IL6 mRNA and protein quantities <sup>158</sup>. The promoter polymorphism G(-174)C, together with nearby polymorphisms, have been the subject of several kidney Tx studies (Table 1).

#### 1.5.1.5 Interferon gamma

Activated T cells produce IFNG. Mitogens for T cells may mimic this induction. IFNG has several properties: it modulates immune activity by e.g. activating macrophages; it mediates the lytic effect; it potentiates the actions of other interferons; and it inhibits intracellular microorganisms other than viruses <sup>159</sup>. The *IFNG* gene lies in 12q15, is 4974 bases long and encodes a protein of 166 amino acids long.

IFNG acts both as an anti-rejection and pro-rejection cytokine, e.g. by induction of microvascularisation in the grafted organ and increasing the expression of MHC. Whether the main effect will be anti- or pro-rejection depends mainly on the secretion time after kidney Tx, being protective early and then later antagonistic <sup>160</sup>. The most studied *IFNG* polymorphisms in kidney Tx are intron 1 SNP T(+874)A and CA short tandem repeat microsatellite (rs3138557). These have been associated with AR, and donor polymorphism to chronic allograft nephropathy (Table 1).

## 1.5.2 Thrombosis-associated genes

The blood coagulation cascade involves several molecules which lead to thrombosis and infarction <sup>161</sup>. In addition, in the epithelium of rejecting graft blood vessels the coagulation cascade activates forming infiltrates in the inflammation area. Infiltrates consist of e.g. platelets, neutrophils and monocytes <sup>162</sup>. All the thrombosis associated genes and polymorphisms studied in this thesis are listed in table 2 where the effect of each molecule is also denoted. The relevant studies to this thesis are discussed in more detail in Results and Discussion.

### 1.5.2.1 Coagulation factor V

The *F5* gene lies in 1q24.2, is 72422 bases long and encodes a protein of 2224 amino acids long. In the context of kidney Tx the factor V Leiden mutation (FVL, *F5* R506Q, G1691A) is currently the most thoroughly investigated polymorphism of the genes of the coagulation cascade. The FVL mutation associates with thrombotic events, rejection episodes, GS and infarction. Patients with the FVL mutation are often given anti-thrombotic prophylaxis. However, in some studies investigators have been unable to demonstrate any association between the FVL mutation and outcome of renal Tx (Table 2). A second *F5* mutation (*F5*R2, H1299R, A[R1]4070G[R2]) occurs in the B-domain of the protein that is released upon the activation of *F5*. The H1299R mutation is postulated to lower *F5* concentrations either by reducing *F5* biosynthesis or increasing *F5* molecule turnover <sup>163</sup>. The effects of the *F5* H1299R mutation on the outcome of kidney Tx have not been previously investigated. In the general population, the *F5* H1299R mutation has been associated with increased risks of infarction and thrombosis <sup>164</sup>.

### 1.5.2.2 Coagulation factor II

The coagulation factor II (*F2*) gene lies in 11p11.2, is 20300 bases long and encodes a protein of 622 amino acids long. The *F2* mutation G20210A changes the *F2* pre-mRNA processing. More *F2* mRNA is translated to the *F2* protein, which leads to increased *F2* concentrations and elevated risk of thromboembolism <sup>165</sup>. The G20210A mutation associates with decreased GS after kidney Tx (Table 2). However, in other studies the results have been conflicting (Table 2).

### 1.5.2.3 Methylenetetrahydrofolate reductase

The methylenetetrahydrofolate reductase (*MTHFR*) gene lies in 1p36.22, is 20335 bases long and encodes a protein of 656 amino acids long. An *MTHFR* mutation (A223V, C677T) results in elevated plasma homocysteine quantities and higher risk of thrombosis secondary to cytotoxic effects on endothelial cells. In kidney Tx, the mutation has been associated with AR and the development of chronic allograft nephropathy, but not with decreased patient or GS (Table 2).

### 1.5.2.4 Protein C, tissue factor pathway inhibitor, coagulation factor XIII

Protein C (*PROC*), tissue factor pathway inhibitor (*TFPI*) and coagulation factor XIII (*F13A1*) are also candidate genes for thrombosis but these have not been studied in kidney Tx patients. The *PROC* gene lies in 2q14.3, is 10802 bases long and encodes a protein of 461 amino acids long. *PROC* inactivates e.g. factor Va, thereby inhibiting clot formation. The *PROC* W380G, T8853G loss-of-function mutation, which may be regarded as a member of the 'Finnish disease heritage' <sup>166</sup>, results in a deficiency of *PROC*, and an increased risk of thrombosis. The *TFPI* gene lies in 2q32.1., is 87880 bases long and encodes a protein of 304 amino acids long. The pro-thrombotic *TFPI* mutation (P151L, C536T) is thought to increase prothrombinase complex activity and thrombin production <sup>167</sup>. The *F13A1* gene lies in 6p25.1, is 176584 bases long and encodes a protein of 732 amino acids long. *F13A1* mutation (V34L, G103A) is associated with protection from thrombosis. The mutated protein has a lower ability to catalyze fibrin polymer formation than the wild type protein. In a recent meta-analysis of diagnosed thrombosis cases and controls in the general population, the V34L mutation had a significant protective effect against thrombosis (homozygote odds ratio (OR) 0.63, 95% confidence interval (CI) 0.46 - 0.86) <sup>168</sup>.



Table 2. A summary of findings in the current literature demonstrating association or lack of association for each described genetic variation on graft outcome (AR, cardiovascular complications and markers, GS or patient survival).

Gene polymorphism, aminoacid and nucleotide change	Allele function	Effect	dbSNP rs number	Citation	
				Association	No association
F5, R506Q, G1691A	1691A allele: Inactivation site mutation, increased coagulation <sup>169</sup>	Factor Xa activation	rs6025	170-175	89,176-180
F2, -, G20210A	20210A allele: Pre-mRNA cleavage site mutation, increased F2 production <sup>165,181</sup>	Factor XIII and fibrinogen activation	rs1799963	175,182	89,178-180
MTHFR, A223V, C677T	677T allele: Decreased enzyme activity, increased homocysteine production <sup>183</sup>	Procoagulation	rs1801133	175,184-192	89,180,193-196, donor: 184,193

### **1.5.3 Other genes studied in renal transplantation**

Polymorphisms in other genes such as cytokines *LTA*, interleukin 1, interleukin 2, interleukin 4, chemokines like chemokine ligand 5, chemokine ligand 12, chemokine receptor 2, chemokine receptor 5, melanin concentrating hormone receptor 1, monocyte chemotactic protein-1, adhesion molecules like intercellular adhesion molecule 1, platelet/endothelial cell adhesion molecule, selectins, costimulatory molecules like cytotoxic T-lymphocyte-associated protein 4, CD28 molecule, renin-angiotensin system molecules like angiotensin I converting enzyme 1, angiotensinogen, angiotensin type 1 receptor, angiotensin type 2 receptor, cytochrome P450 family 11 subfamily B polypeptide 2, and other molecules like growth factors and G proteins have also been studied in the kidney Tx setting <sup>99</sup>. However, these individual reports await confirmation from replication studies. Candidate gene studies may become fewer as they are replaced by future GWA studies. The only so far published GWA study from Tx patients was a case-control association study using 50,947 gene-based SNPs to identify genetic variations that might be associated with cardiovascular risk factors in 72 renal transplant recipients with cyclosporine therapy. The results were used to analyse predictive performance of cardiovascular risk factors associated with SNPs <sup>197</sup>. The Transplant Genomics Collaborative Group is conducting a GWA study on kidney Tx recipients and donors ([www.genetics.ucla.edu/transplant-genomics/research/programs/project3.php](http://www.genetics.ucla.edu/transplant-genomics/research/programs/project3.php)).

## **1.6 METHODS AND BIOMARKERS STUDIED BY THESE METHODS FOR DIAGNOSING ACUTE REJECTION**

Biomarkers are variables or predictors of a specified clinical condition measured by various laboratory methods. These variables may change over time according to the progression of the disease. Biomarkers have conventionally been protein molecules measured from bodily fluids or tissue biopsies. Gene expression and cell surface structure profiling using microarray and flow cytometry or mass spectrometry are the latest methods used <sup>198</sup>. In the next sections biomarkers are reviewed according to the method used.

### 1.6.1 Histology

A radiologist or nephrologist takes the kidney biopsy and a pathologist interprets the histologically stained sample and in some cases the sample is further stained with specific antibodies to molecules specific for AR subtypes. Histopathological evaluation may allow the identification of the cause of acute allograft dysfunction e.g. acute tubular injury, calcineurin inhibitor toxicity, obstruction or various inflammatory infiltrate processes. Standardization of renal allograft biopsy interpretation is necessary to guide therapy and to establish an objective end point for clinical trials. The first meeting for this purpose was in Banff, Canada in 1991, to develop an international classification for the histological grading of solid organ transplants. The biennial congresses have reported their proceedings in peer reviewed journals since the international consensus discussion began at Banff, and the process continues via the internet ([cybernephrology.ualberta.ca/Banff/](http://cybernephrology.ualberta.ca/Banff/)). In the Banff schema, kidney biopsy findings are rated and categorized to assist diagnosis and therapy. Banff 97 classification "defines types of acute/active rejection. Type I is tubulointerstitial rejection without arteritis. Type II is vascular rejection with intimal arteritis, and type III is severe rejection with transmural arterial changes. Biopsies with only mild inflammation are graded as borderline/suspicious for rejection. Chronic/sclerosing allograft changes are graded based on severity of tubular atrophy and interstitial fibrosis. Antibody-mediated rejection, hyperacute or accelerated acute in presentation, is also categorized, as are other significant allograft findings"<sup>199</sup>. Antibody mediated rejection in particular is diagnosed using immunostaining of capillaries or arteries for C4d<sup>200</sup>. Other molecules associating with AR include B7-1, B7-2, CD14, CTLA4, allograft inflammatory factor-1, TNF, IL18 and growth arrest-specific gene 6<sup>201-205</sup>. Moreover, AR does not associate with molecules such as CD20, CD40, CD40L, CD25, perforin, TNF and TGFB1<sup>201-203,206,207</sup>. In the future, biopsy sections may be stained with a wider repertoire of antibodies to explore the molecular pathway involved in the rejection process<sup>208</sup>.

The latest Banff classification from 2005 has abandoned the non-specific term chronic allograft nephropathy and recognizes the entity of chronic antibody-mediated rejection. Renal biopsies are classified to six classes: 1. normal, 2. antibody-mediated rejection, 3. borderline changes, 4. T-cell-mediated rejection, 5. interstitial fibrosis and tubular atrophy, 6. other changes not considered to be due to acute and/or chronic rejection<sup>209</sup>.

In addition, a clinician may take a fine needle aspiration biopsy (FNAB) <sup>210</sup>. The FNAB samples are scored according to a total corrected increment (TCI) value which is based on counting immunoblasts, activated lymphocytes, plasmablasts and activated monoblasts in the cytological samples <sup>211</sup>. FNAB can be used as a frequent monitoring of AR in kidney graft <sup>212</sup>. However, FNAB cannot identify vasculitis and tubulitis, which are important components of the Banff grading systems for rejection <sup>213</sup>.

### **1.6.2 Enzyme-linked immunoabsorbent assay**

Enzyme-linked immunoabsorbent assay (ELISA) is an immunoassay utilizing an antibody labelled with an enzyme marker. The enzyme or the antibody is bound to an immunosorbent substrate, and the change in enzyme activity from the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured e.g. spectrophotometrically <sup>214</sup>. The risk of AR can to some degree be estimated by determination of pretransplant anti-HLA antibodies. One of the methods used is the ELISA, where solubilized class I or class II HLA antigens are fixed onto microtiter plates. Antibodies against both HLA class I and class II increase rejection episodes in *HLA* mismatched first grafts. ELISA assay is perhaps more sensitive for detecting additional antibodies with clinical relevance. However, it cannot detect other Tx-relevant non-HLA antigens or isotype antibodies other than IgG <sup>215</sup>.

Another pre-transplant test for predicting rejection is measurement of soluble CD30 (sCD30), most often using ELISA. CD30 is preferentially expressed on Th2-type T cells with alloimmune responsiveness. Elevated quantities of sCD30 are associated with increased risk of AR, independently of anti-HLA antibodies or Tx sequence <sup>215</sup>. However, in the Finnish Tx, the quantities of sCD30 did not predict rejection incidence <sup>216</sup>; but on day 21 posttransplant the rejecting patients had significantly higher relative sCD30 quantities than the non-rejecting patients <sup>216</sup>. A pilot study implied that high sCD30 quantities at post-Tx days 3 to 5 predicted AR well <sup>217</sup>. In addition, pre- and post-transplant CD40 quantity predicts AR. CD40 is expressed in injured kidney and is involved in the extravasation of lymphocytes at sites of inflammation <sup>218,219</sup>. From other molecules, the upregulation of IL10, IL12, IL18, macrophage-colony stimulating factor (M-CSF), IFNG, and the downregulation of IL4, associate with AR <sup>204,220,221</sup>. In addition in other studies, molecules IFNG, sIL1RA, IL2, sIL2R, IL3, IL4, IL6, sIL6R, IL10, TGFB2, TNF have not associated with AR when studied with ELISA <sup>222,223</sup>. However, internationally transplantation centres do not use any of these routinely.

### **1.6.3 Fluorescence activated cell sorting**

In fluorescence-activated cell sorting (FACS) a monocellular stream of cells, platelets or other microscopic particulate elements is passed through a beam of laser light of a computerised instrument which categorises them by size and form. Cells can be labelled with fluorescent dye and a laser based detector system used to excite fluorescence and give fluorescent cell droplets an electric charge. Cells can subsequently be separated and collected and/or counted <sup>224</sup>. Anti-HLA antibodies can be detected using FACS analysis. In one application, patient serum reacts with beads coated with specific HLA antigens and anti-HLA antibodies are detected by fluorescence-conjugated anti IgG or IgM antibodies <sup>225</sup>. If antibodies are found these can be further specified to certain HLA antigens with another FACS analysis using beads coated with single HLA antigens <sup>226</sup>. High titer post-Tx HLA antibodies monitored by FACS bead analysis are associated with increased rejection incidence <sup>227</sup>.

AR diagnostics with FACS analysis is based on specific antibodies, which detect their antigens at the surface or inside recipient cells. The T lymphocyte surface molecule CD69, a marker for T cell activation, associates with AR <sup>228</sup>. Other associations with AR are downregulation of CD45 and upregulation of CD61, CD63 and PAC-1 <sup>229,230</sup>.

### **1.6.4 Mass spectrometry**

Mass spectrometry measures the mass-to-charge ratio of ions. The main components of a mass spectrometer are an ionization source, a mass analyzer, and a detector system <sup>231</sup>. All methods described above have been applied to the candidate molecules derived from studies where the known pathways of AR or alloimmunity were investigated. A recent research approach that has become feasible for well-funded research centres is global protein analysis based on mass spectrometry with or without two-dimensional gel electrophoresis. Global urine protein profiling has been proposed as a potential non-invasive method for AR monitoring in kidney Tx, and several studies have been published <sup>232-239</sup>. However, large consortiums have yet to publish their results ([www.allomark.ubc.ca/](http://www.allomark.ubc.ca/) and [www.genetics.ucla.edu/transplant-genomics/research/programs/project2.php](http://www.genetics.ucla.edu/transplant-genomics/research/programs/project2.php)). They may discover novel molecules associated with AR that can be monitored with routinely used methods like ELISA AR and other outcomes.

### **1.6.5 TaqMan real-time quantitative polymerase chain reaction**

TaqMan RT-QPCR (from now on referred to as RT-QPCR) is based on the two sequence specific primers and a probe, fluorescently labelled with a reporter and quencher dye. In the PCR extension phase Taq polymerase cleaves the hybridized probe and releases the reporter dye for fluorescence detection <sup>240</sup>. Real-time quantification can be done with various instruments that vary in excitation and emission wavelengths available, speed, number of reactions that can be run in parallel, and the reaction container. However, the software and performance of these instruments are basically identical <sup>241</sup>. The statistical analysis of RT-QPCR has not reached a consensus, with standard curve and  $\Delta\Delta Ct$  relative expression methods being most commonly used <sup>242</sup>. In the standard curve method the efficiency of PCR reactions is taken into account by running known dilutions of the studied gene and a reference gene from one sample in every RT-QPCR run. In the  $\Delta\Delta Ct$  method the efficiency of PCR reactions is validated to be the same in the studied gene and the reference gene and dilutions are not run after validation run <sup>243</sup>.

RT-QPCR studies in the kidney Tx setting for AR markers are listed in Table 3. Results may reflect different sources of sample material, like kidney biopsy, urine or different blood components, and different methods for RT-QPCR. Studies relevant to this thesis are discussed in more detail in Results and Discussion.

### **1.6.6 Microarray**

Microarray is quite young as a method, the results of the first self-made cDNA arrays being published in 1995 <sup>244</sup>. Commercially manufactured oligoarrays, in particular those by Affymetrix, together with centralised core facilities have made the technique available to all users. Even though the first kidney Tx microarray studies were all performed with self-made cDNA arrays <sup>245-256</sup>, studies have also been done with commercially available chips <sup>257-259</sup>. While gene expression can be studied from any cellular source, kidney Tx has obvious sources that may indicate what is going on in the graft and recipient, i.e. the blood, urine and biopsy from the graft. From these sources RNA is isolated and purified. Often there is too little RNA for direct hybridization to the arrays. RNA is therefore amplified, followed by labelling and hybridization onto the array chips. A scanning apparatus reads the results. The raw data must be normalized

using an appropriate technique and the samples are compared by various statistical methods depending on the hypothesis. All this processing makes the comparison of studies very difficult, but not impossible. Based on microarray analysis only, there are no commercial laboratory tests available that would utilize novel biomarkers. However, there are two consortiums developing new biomarkers based on the combination of proteomics and genomics ([www.allomark.ubc.ca/](http://www.allomark.ubc.ca/) and [www.genetics.ucla.edu/transplant-genomics/research/programs/project2.php](http://www.genetics.ucla.edu/transplant-genomics/research/programs/project2.php)), and if clinically relevant, their results are to be made available as a commercial test package.

Many candidate gene markers are expressed in such low quantities that not all microarrays can detect the expression of the studied genes. These include many cytokines which are major contributors to the rejection process. However, RT-QPCR can be used to quantify the low expressing genes <sup>260</sup>.

Until now (November 2007), four studies have investigated clinical rejection but not subclinical rejection in human kidney Tx using human samples in microarrays <sup>248,252,261,257</sup>. All have been done with different microarray platforms and only one <sup>257</sup> has reported a comparison of biopsy to peripheral blood leukocyte (PBL) samples. The comparison of immune response genes in the microarray studies shows that different genes are significantly upregulated or downregulated (Table 4). The biomarkers in Transplantation and Transplant Genomics Collaborative Groups are conducting a whole genome expression study from kidney Tx recipients and donors ([www.allomark.ubc.ca/](http://www.allomark.ubc.ca/) and [www.genetics.ucla.edu/transplant-genomics/research/programs/project1.php](http://www.genetics.ucla.edu/transplant-genomics/research/programs/project1.php)). Rapid advances in technology may bring expression analysis into clinical use in the next few decades <sup>263</sup>.

Table 3. Summary of the current literature on RT-QPCR studies demonstrating association or lack of association for each described gene for predicting AR.

Sample source	Gene	Function	Association	Citation
Kidney biopsy	perforin 1 (PRF1, Per)	Cytotoxic molecule, membrane-perturbing protein	264-270	271, 272
	fas ligand (FASLG, FL)	Cytotoxic molecule, T cell effector protein	265, 266, 268-273	264
	granzyme B (GZMB, GB)	Cytotoxic molecule, granule serine protease	264-266, 268, 269, 272-274	270, 271
	granulysin (GNLY, Gra)	Cytotoxic molecule, membrane-perturbing protein	268	
	CD40 ligand (CD40LG, CD154)	Costimulatory molecule, positive effect on T cell signalling	268	
	inducible T cell co-stimulator (ICOS)	Costimulatory molecule, positive effect on T cell signalling	268	
	cytotoxic T-lymphocyte-associated protein 4 (CTLA4)	Costimulatory molecule, inhibitory effect on T cell signalling	264, 268	265
	programmed cell death 1 (PDCD1, PD-1)	Costimulatory molecule, inhibitory effect on T cell signalling	268	
	perforin 1 (PRF1, Per)		275-279	280
	fas ligand (FASLG, FL)		278, 279	280
Blood	granzyme B (GZMB, GB)		275, 276, 278, 279, 281	280
	perforin 1 (PRF1, Per)		266, 282-286	251, 270, 287-289
	fas ligand (FASLG, FL)		266	270, 282, 283, 285, 287, 289
	granzyme B (GZMB, GB)		251, 266, 282, 283, 286, 288	270, 285, 287, 289
	granulysin (GNLY, Gra)		251, 290	289
	CD40 ligand (CD40LG, CD154)		287, 289, 291	
	inducible T cell co-stimulator (ICOS)		289	
	cytotoxic T-lymphocyte-associated protein 4 (CTLA4)			289
	programmed cell death 1 (PDCD1, PD-1)			289



Table 4. Microarray studies in kidney Tx with AR as outcome <sup>255</sup>.

Refer- ence	Platform	Tissue	Sample number	Selected key genes	Gene category
<sup>257</sup>	Oligonucleotide (Affymetrix HG- U95Av2)	Kidney biopsy, PBL	32 (7 AR)	AIF, CD14, CD163, CD2, CD3D, CD48, CD53, chemokines, interleukins, C1q, immunoglobulins, INFG, TCR, TNF, and HLA	Immune response, inflammation, cell cycling, and DNA metabolism
<sup>252</sup>	Custom cDNA (number of transcripts not reported)	Kidney biopsy	26 (AR subtypes)	HLA Class I and II, CD20, MIG, MIP-1, CCR5, CX3CR1, DARC, SCYB10, SCYA5, SCYA3, SCYA13, SCYA2, interleukins, DEFA1, DEFB1, SCYA2, SCYA5, MST1, STAT1, STAT6, CD69, MAL, NFATC3, annexins, CASP10, PECAM1 and VCAM1	T- and B-cell acti- vation, immune response, apopto- sis, cell adhesion, cell cycling, HLA genes, and innate immunity
<sup>248</sup>	Custom cDNA (28032 transcripts)	Kidney biopsy	67 (25 AR)	TCR, HLA class I and class II, immunoglobulins, lactotransferrin, chemokines, CD20, CD34, IGF1R, TNFR, MST1, NK4, DARC, STAT1, TGFR1, GZMA, PRF1, IL2R, CD53, LTA, LTBR, NFKB1, CD59, IFNGR1, and annexins	Immune response (T and B cell), in- nate immunity, apo- ptosis, transcrip- tional regulation, and cell cycling
<sup>261</sup>	Oligonucleo- tide (Affymetrix Hu6800)	Kidney biopsy	10 (7 AR)	CXCL9, TCR, RING4, ISGF-3, CD18	Immune response

## 2 AIMS OF THE STUDY

The present thesis investigates the role of genetic factors in the clinical outcome of kidney Tx. In addition to the currently performed histocompatibility testing several other genetic factors may influence the outcome of kidney Tx and these factors could potentially be analysed and the results used to improve patient care.

We hypothesized that cytokine and/or thrombosis associated gene polymorphisms may predict the outcome of kidney Tx in adults, because cytokines are major mediators of immunological responses in Tx, in CMV infection and cytokines and coagulation cascade molecules are mediators of immunological responses in the vessels of transplanted organs.

In addition, we hypothesised that by studying gene expression quantities on blood samples using microarrays and/or RT-QPCR, we could determine the clinical applicability of a non-invasive method to diagnose AR or SCR in kidney Tx.

Specific aims:

- 1) To study the association between specific SNPs in genes *TNF*, *TGFB1*, *IL10*, *IL6*, *IFNG*, *F5*, *F2*, *F13A1*, *PROC*, *TFPI*, and *MTHFR* and outcomes in kidney Tx.
- 2) To study the association between AR and gene expression of *Per*, *FL*, *GB*, *Gra*, *CD154*, *ICOS*, *CTLA4*, and *PD-1*.
- 3) To study the association between SCR and gene expression of *CD154*, *ICOS*, immunologically related genes, and whole genome gene expression.

### 3 PATIENTS

**Study I.** The retrospective study comprised 291 adult cadaver kidney recipients and their 206 donors transplanted between 1999 and 2002 at the Renal Transplant Unit of Helsinki University Hospital, Finland.

**Study II.** The retrospective study comprised 71 CMV seronegative recipients of kidney grafts from 62 CMV seropositive donors transplanted between 1999 and 2002 at the Renal Transplant Unit of Helsinki University Hospital, Finland.

**Study III.** The prospective study comprised 50 adult renal graft recipients transplanted between 2001 and 2005 at the Renal Transplant Unit of Helsinki University Hospital, Finland.

**Study IV.** The retrospective study comprised 772 adult cadaver kidney Tx's for 764 recipients (eight recipients had 2 Tx's during the study period) and their 462 donors transplanted between 1999 and 2003 at the Renal Transplant Unit of Helsinki University Hospital, Finland.

**Study V.** The prospective study comprised 31 consecutive paediatric kidney allograft recipients transplanted between 2003 and 2006 at the Hospital for Children and Adolescents of Helsinki University Hospital, Finland.

### 4 ETHICAL PERMITS

Ethical permits for the studies were obtained from the relevant Ethical Committees of Helsinki University Hospital.

## 5 METHODS

### 5.1 Isolation of DNA (I, II, IV)

Whole blood samples were originally taken before transplantation for histocompatibility testing. The extracted DNA or buffy coats from citrate anticoagulated peripheral blood were stored at -20°C. DNA was extracted using the QIAamp DNA Blood Mini Kit (QIAGEN Inc, CA) or the FlexiGene DNA Kit (QIAGEN Inc, CA, USA).

### 5.2 Human leukocyte antigen typing (I)

For *HLA-A* and *HLA-B* typing serological lymphocytotoxicity method and for *HLA-DRB1* typing INNO-LiPA *HLA-DRB1* kit were used (Immuno Diagnostic Oy, Hämeenlinna, Finland).

### 5.3 Determination of single nucleotide polymorphisms (I, II, IV)

The SNPs for this study were chosen based on literature review of most promising candidate gene polymorphisms predicting the outcome of kidney Tx. Genetic variations in *TNF* G(-308)A, *TGFB1* T(+869)C and C(+915)G, *IL10* G(-1082)A, *IL10* C(-819)T, and C(-592)A, *IL6* G(-174)C, and *IFNG* T(+874)A genes of recipients and donors of studies I and II were determined using the Cytokine Genotyping Kit (One Lambda Inc. CA, USA). Study IV recipients and donors were genotyped for *F5* G1691A rs6025, *F5* A4070G rs1800595, *F2* G20210A rs1799963, *F13A1* G204T rs5985, *PROC* T8853G, *TFPI* C536T, and *MTHFR* C677T rs1801133, and those not included in study I also for *TNF* G(-308)A rs1800629, *IL10* A(-1082)G rs1800896, *IL10* C(-592)A rs1800872, and *IL6* C(-174)G rs1800795 at the Finnish Genome Centre, University of Helsinki, Finland, using the Sequenom MassARRAY system, based on MALDI-TOF technology and primer extension chemistry<sup>292</sup>. In addition, a few samples were only or also tested for *F5* G1691A rs6025 and *F2* G20210A rs1799963 at the Thrombosis Laboratory of the Finnish Red Cross Blood Service using a Factor V Leiden Kit and Factor II (Prothrombin) G20210A Kit (LightCycler® Instrument, Roche Diagnostics GmbH, Mannheim, Germany).

## **5.4 Isolation, quantification and validation of RNA from whole blood (III, V)**

In study III 119 and in study IV 52 whole blood samples were drawn into Paxgene Blood RNA tubes (PreAnalytiX, Qiagen Nordic) and stored within 24 hours at -70°C until RNA purification. RNA was purified using the Paxgene Blood RNA kit (PreAnalytiX, Qiagen Nordic) according to the kit protocol and with an on-column DNase I treatment. The RNA was quantified with a GeneQuant™ pro RNA/DNA Calculator (GE Healthcare, Finland). The integrity of the isolated RNA was verified by electrophoresis using ssRNA Ladder Sample Buffer and ssRNA Ladder (New England Biolabs, USA).

## **5.5 Real-time quantitative polymerase chain reaction (III, V)**

Synthesis of cDNA from isolated total RNA was done with a High Capacity cDNA Archive Kit (Applied Biosystems, Finland) according to the manufacturer's instructions. The relative gene expression was quantified using TaqMan Gene Expression Assays (Applied Biosystems, Finland), TaqMan Universal PCR Master Mix with no AmpErase UNG (Applied Biosystems, Finland) and ABI PRISM 7000. The probe and primer assays used in the studies are listed in Table 5. The endogenous control gene *PGK1* was chosen from a TaqMan Human Endogenous Control Plate (Applied Biosystems, Finland) as the stably expressed gene among three recipients with a concurrent rejection episode and their post-treatment samples. The relative expression was calculated using the standard curve method (User Bulletin 2, P/N 4303859B, Applied Biosystems) using one non-patient volunteer as a calibrator sample.

Table 5. Quantified genes in studies III and V.

<b>Gene</b>	<b>Abbreviations</b>	<b>Assay identification code</b>
perforin 1	PRF1, Per	Hs00169473_m1
fas ligand, tumor necrosis factor (ligand) superfamily, member 6	FASLG, FL	Hs00181225_m1
granzyme B	GZMB, GB	Hs00188051_m1
Granulysin	GNLY, Gra	Hs00246266_m1
tumor necrosis factor (ligand) superfamily, member 5	CD40LG, CD154	Hs00163934_m1
inducible T cell co-stimulator	ICOS	Hs00359999_m1
cytotoxic T-lymphocyte-associated protein 4	CTLA4	Hs00175480_m1
programmed cell death 1	PDCD1, PD-1	Hs00169472_m1
phosphoglycerate kinase 1	PGK1	Hs99999906_m1
transformer-2 alpha	TRA2A	Hs00203263_m1
interferon regulatory factor 2 binding protein 2	IRF2BP2	Hs00766250_g1
myristoylated alanine-rich protein kinase C substrate	MARCKS	Hs00158993_m1
transportin 1	TNPO1	Hs01007848_g1
solute carrier family 8 member 1	SLC8A1	Hs01062251_m1
homeodomain interacting protein kinase 1	HIPK1	Hs00380232_m1
Calreticulin	CALR	Hs00944361_g1
IQ motif containing GTPase activating protein 1	IQGAP1	Hs00896582_g1
Dcr-1 homolog (Drosophila)	DICER1	Hs00998583_g1
lysophospholipase I	LYPLA1	Hs00377829_g1
PRO1073 protein/metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA)	PRO1073/ MALAT1	Hs00273907_s1
CD3e molecule, epsilon (CD3-TCR complex)	CD3E	Hs00167894_m1
B-cell CLL/lymphoma 2-like 1	BCL2L1	Hs00169141_m1
polycomb group ring finger 5	PCGF5	Hs00260713_m1
CGI-69 protein	CGI-69	Hs00924962_g1
BCL2-associated athanogene	BAG1	Hs01105460_g1
N-ethylmaleimide-sensitive factor attachment protein alpha	NAPA	Hs00943303_m1
FK506 binding protein 8 38kDa	FKBP8	Hs01014666_g1

## 5.6 Low-density array (V)

RT-QPCR from 90 immune-related and six housekeeping genes 18S ribosomal RNA, beta actin, glyceraldehyde-3-phosphate dehydrogenase, *PGK1*, beta glucuronidase and transferrin receptor was performed in a low-density array format at the Section for Medical Genetics and Molecular Medicine, University of Bergen, Norway, according to the manufacturer's protocol (TaqMan® Low Density Human Immune Panel card, 4370573, Applied Biosystems). The amount of cDNA counted from RNA concentration was 1 µg per card.

## 5.7 Microarray (V)

After isolation, 5 µg of RNA was treated using the Globin Reduction Protocol according to the manufacturer's directions (Globin Reduction Protocol: A Method for Processing Whole Blood RNA Samples for Improved Array Results Part No. 701497 Rev. 2, [www.affymetrix.com](http://www.affymetrix.com)). All experiments were performed using Affymetrix Human Genome U133 Plus 2.0 oligonucleotide arrays according to the manufacturer's directions. Sample labelling and hybridisation were carried out at the Finnish DNA Microarray Centre at Turku Centre for Biotechnology, Turku, Finland.

The Affymetrix GeneChip Operating Software (GCOS) detection algorithm was used to determine the presence or absence of expression for each transcript. A transcript with either a present or a marginal detection call was considered expressed. The complete gene expression data are available at <http://qp01.novogroup.com/vpu>. The GCOS change algorithm was used to compare the data of patients with rejection at three months post-Tx against the same patient's six-month post-Tx sample data, or against the data of patients without rejection at three months, to detect and quantify changes in gene expression. The transcripts assigned with increased, decreased, marginally increased or marginally decreased change calls were considered differentially expressed. Only those genes that were increased or decreased by at least a two-fold change in all rejection patients compared with normal patients at three or six months were studied further.

## 5.8 Statistical analyses (I - V)

Preliminary power analysis was done with the Genetic Power Calculator<sup>293</sup> based on known baseline characteristics (odds ratio 3 - 10 according to outcome and SNP) and results published by others on the incidence of the studied factors (IV)<sup>170,175,182</sup>. The Hardy-Weinberg equilibrium of genotypes was tested using Fisher's Exact Test (I, II, IV). Descriptive statistics were used to describe the baseline characteristics and duration of follow-up. In bivariate analysis, Fisher's exact test was used to compare the occurrence of AR, thrombosis, infarction or composite endpoint from the above with respect to categorical baseline characteristics. Corrections for multiple testing were not done and a P-value <0.05 was considered statistically significant in studies I - III and V. The correction for multiple testing was done using the Bonferroni correction according to 11 DNA polymorphisms studied in 9 candidate genes without taking into consideration the number of studied phenotypes that give statistically significant P-values less than 0.0045 (IV). In addition, the distributions of continuous baseline characteristics with respect to studied complications and available laboratory results after Tx were compared using a Mann-Whitney U test and a Kruskal-Wallis test. Bivariate survival analysis was done with a Kaplan-Meier analysis and log rank test (II - IV). To adjust for confounding factors, multivariate logistic regression (I, II, IV) and Cox proportional hazards models (II, IV) were used to analyse the risk factors associated with AR, thrombosis, infarction, composite endpoint or 1st year GS after Tx. Statistical analyses were done using SPSS 13.0.1 (SPSS, Finland), StatsDirect 1.8.10 (StatsDirect, UK) or MedCalc 8.1 (MedCalc Software, Belgium).



## 6 RESULTS AND DISCUSSION

### 6.1 Acute rejection (I, IV)

Studies I and IV aimed to find associations between SNPs and AR, thrombosis, infarction, or GS. Such findings would justify further study of the associations prospectively in a larger study population. Eventually it might be possible to determine whether asymptomatic patients would benefit from individualized immunosuppression, antithrombotic prophylaxis or other medication according to their genetic status.

The overall incidence of AR in the study I was 17.2 %, i.e. 50 episodes. Two pre-transplantation factors were found to increase the risk of AR: presence of 3 - 4 *HLA-A*, *-B* or *-DR* mismatches (MM) (OR 1.8, 95 % CI 1.1 - 3.1 and  $P = 0.027$ ), and a graft from CMV-seronegative donor to CMV-seronegative recipient increased the risk of AR (OR 2.2, 95 % CI 1.2 - 4.1,  $P = 0.038$ ).

The cytokine gene polymorphisms studied in study I were *TNF* G(-308)A, *TGFB1* T(+869)C and C(+915)G, *IL10* G(-1082)A, *IL10* C(-819)T, and C(-592)A, *IL6* G(-174)C, and *IFNG* T(+874)A. *TNF* and *IL10* are the cytokine genes previously reported as most likely to have relevance for allograft outcome <sup>154</sup>. In addition, *IFNG*, *IL6* and *TGFB1* have in some studies been found to have an impact on the development of AR <sup>96,128,135,294</sup>. All of these studies were relatively small of under 200 recipient or donor participants, the obtained p-values were rarely clearly less than 0.05 or corrected for multiple testing and usually derived from only a few SNPs. However, these were the SNPs most studied and associated positively to kidney Tx outcomes so we limited the scope of the study to these five genes.

Among 772 transplant recipients in study IV, an AR episode was diagnosed in 139 (18%) subjects. We genotyped *F5* G1691A, *F5* A4070G, *F2* G20210A, *F13A1* G204T, *PROC* T8853G, *TFPI* C536T, *MTHFR* C677T, *TNF* G(-308)A, *IL10* A(-1082)G, *IL10* C(-592)A, and *IL6* C(-174)G, giving a total of 11 SNPs in nine genes in the study IV. This resulted in a Bonferroni corrected significant P-value of 0.005. None of the SNPs were significantly associated with AR. The level of *HLA* mismatch (Hazard ratio (HR) 2.3, 95% CI 1.6 - 3.3), DGF (HR 1.8, 95% CI 1.2 - 2.6) and the age of recipient (HR 0.97, 95% CI 0.96 - 0.99) showed association with AR by Cox proportional hazard model. The last mentioned two known risk factors were also statistically significant in bivariate analysis and in logistic regression analysis.

### **6.1.1 Only a few gene polymorphisms were associated with acute rejection (I)**

The distribution of the frequencies of the cytokine genotypes was found to be in the Hardy-Weinberg equilibrium. There were no differences in frequencies between the recipients and donors. The cytokine polymorphisms at genotype level in the recipient and respective donor were compared by univariate analysis with respect to AR status (I). The recipient *TNF* -308AA genotype was statistically significantly associated with AR (Rejection rate 80%, OR = 5.0, P = 0.0034).

Chronic rejection triggers *TNF* production in stimulated monocyte cultures of affected patients <sup>295</sup>. In addition, *TNF* is more often detected in plasma and urine in renal allograft recipients with AR <sup>296</sup>. The dbSNP lists more than 37 polymorphisms at the 5' end of the *TNF* gene, of which the G(-308)A (rs1800629) SNP is probably the most frequently studied. After HapMap project and other extensive resequencing projects, it is now known that only 3 SNPs (among them -308) are needed to capture 80 % of the common genetic variation in *TNF* overall among European-Americans <sup>297</sup>. More extensive approach by studying all the *TNF* SNPs in a small number of samples and defining the LD between them was out of reach of this study, even though this would have given more information about the definitive SNP affecting the association between *TNF* and AR. *TNF* -308A allele is considered a six- to seven-fold stronger activator of transcription than the more common G allele <sup>110</sup>. However, Bayley et al. reported that the -308 SNP had no functional relevance for *TNF* transcription <sup>298,299</sup>. Probably due to conflicting results in expression studies, the reported effects of *TNF* A(-308)G SNP on Tx outcome have been variable. The -308 SNP was found to be associated with AR in heart <sup>300</sup> and renal allograft recipients and the A allele predisposed to AR in these studies <sup>96,112-114</sup>. A combination of *TNF* -308 AA or GA genotypes with *IL10* -1082AA genotype in the same heart Tx patient significantly increased AR risk <sup>301</sup>. However, several studies of kidney and heart Tx patients have failed to find an association of -308 SNP with AR <sup>98,124,126,127</sup>.

Some of the studies have included small groups (100 - 200 participants) of uniform genetic subjects, e.g. Caucasians and African-Americans, having genetic backgrounds with different risk factors <sup>98</sup>. Further, multivariate analysis has not always been performed due to missing clinical factors (known or hypothesized confounding factors) or insufficient numbers of subjects (not enough power perform subgroup analyses) <sup>96,114,127</sup>. The multivariate analysis in the present study was done with both a prior hypothesis and hypothesis-free approaches.

However, the impact of genetic factors in predicting AR was small and did not exceed the impact of known clinical factors.

In published reports the genotype frequencies that may suggest that the Hardy-Weinberg equilibrium is not fulfilled are usually not listed, probably due to lack of space or because of being perceived as uninteresting to a journal audience. In addition, the studied outcome incidences vary to a large degree, probably reflecting major variances in the amount of immunosuppression administered to patients <sup>124,126</sup>. This may mask or inflate the reported importance of the studied SNPs by altering the observed association of outcome with gene polymorphisms.

*TNF* and *HLA* genes are in strong LD <sup>302</sup>. Only some studies take this into account as a confounding effect when considering *HLA* mismatches between recipients and donors and *TNF* gene polymorphisms associating with outcome <sup>96,112,127,301,303</sup>. The *TNF* -308A-allele lies within the *HLA-A1-B8-DR3-DQ2* extended haplotype which is associated with various autoimmune diseases e.g. IgA deficiency and systemic lupus erythematosus <sup>304</sup>. In our study, the *HLA-A1-B8-DR3* haplotype was not associated with AR despite the recipient *TNF* -308AA genotype being associated with AR.

In addition, *IL10* polymorphisms have been reported to associate with AR in several reports <sup>98,112,123,134</sup>, but not in others <sup>96,113,124,126,127,135</sup>. Contradictory results may in part be result of insufficiently powered studies. Gene polymorphisms in the *IL10* gene have been found to constitute conserved haplotypes in many populations (only certain haplotypes are found), combined (low and intermediate or high and intermediate are combined) or separate genotypes associating with low, intermediate or high *IL10* protein production *in vitro* <sup>305</sup>. We did not find association between *IL10* -1082AA (low producer) or AG/GG (high producers) genotypes and AR, whether or not they occurred together with the *TNF* -308 AA/AG (high producers) or GG (low producer) genotypes. The *IL10* low/*TNF* high profile associates with AR in heart Tx <sup>301</sup> and the *IL10* high/*TNF* high profile associates with AR in kidney Tx <sup>112</sup>. The association with AR of *IL10* gene polymorphism may be influenced by the allograft, the immunosuppressants used, the criteria of AR diagnosis, and other unknown or known factors between hospitals and studies.

### **6.1.2 Genetic variation in thrombosis-associated or cytokine genes did not associate with AR (IV)**

Heidenreich et al. reported a medium sized prospective study showing an association between AR and *F5* G1691A, *F2* G20210A or *MTHFR* C677T in 165 kidney Tx recipients <sup>175</sup>. Their study had an exceptionally high incidence of AR, 44% as compared to 18% in our study, which may indicate under-immunosuppression in their study. However, our results were similar to the findings of Pherwani et al. who found no association in recipients or donors between AR and *F5* G1691A, *F2* G20210A or *MTHFR* C677T. They reported a retrospective study on paediatric and adult patients who were given heparin for postoperative thrombosis prophylaxis. They did not report overall AR incidence, but their first-year graft failure rate due to AR was 4.1% compared to only 1.4% in our study, suggesting that different immunosuppression and *HLA* matching policy was used <sup>178</sup>.

An advantage of our study was that the Finnish population is genetically relatively homogeneous, which probably helps identification of weaker associations between genetic factors and disease outcome <sup>306</sup>. One might postulate that in the absence of statistically significant genetic associations of the marker polymorphism in the Finnish population, these cannot be found in genetically more mixed populations either, assuming equal prevalences of the marker polymorphism in the populations. The converse may also be true, i.e. that an association of the marker polymorphism significant in the Finnish population may not be found in a more mixed population.

A more ambitious approach than analysis of candidate genes would be a genome-wide analysis of gene polymorphisms, as other genes involved in the thrombotic cascade may associate with AR. However, we studied 11 DNA polymorphisms in nine candidate genes, including eight SNPs not previously studied in a kidney Tx setting, making our investigation the most extensive study of thrombosis-associated polymorphisms in adult kidney Tx so far.

Despite almost 800 Tx in the study IV, the AR incidence was only 18% and several SNPs were found to be quite rare (four rare allele incidences <2%). A larger study material is therefore needed for definite conclusions. We could not replicate the association found in our study I between *TNF* SNP and rejection. This may possibly be due to the first finding being a false positive result. Other possible reasons for non-replication are not correcting for multiple testing in the first study and the inflated OR in the small sample size of *TNF* -308AA genotype carriers.

In conclusion, we were unable to find associations between SNPs and AR in the retrospective adult kidney Tx setting. We could not provide data to support the routine determination of gene polymorphisms before Tx for AR prediction.

## **6.2 Genetic variation in interleukin 10 but not in other cytokine genes predisposed to CMV infection (II)**

We aimed to predict the incidence and timing of CMV infection in adult deceased kidney Tx by analyzing cytokine gene polymorphisms, because cytokines are major mediators of immunological responses to CMV infection and CMV infection may impair kidney graft function after Tx. CMV diagnosis was defined as clinical CMV suspicion (fever and/or elevated serum creatinine value without rejection) and positive pp65 antigenaemia test. This study targeted the high-risk group of CMV serology negative recipients (R-), with CMV serology positive (D+) donors. We genotyped 71 recipients and 62 donors for *IL10* G(-1082)A, *IL10* C(-819)T, and C(-592)A, *IL6* G(-174)C, and *IFNG* T(+874)A cytokine gene SNPs. There were 24 diagnosed CMV episodes. Of the recipients, 22 received three-month CMV prophylaxis of gancyclovir or valgancyclovir and five a short prophylaxis (6-21 days) during a concurrent AR episode. Three-month prophylaxis, immunosuppressive treatment without antibody induction, and normal onset of graft function reduced the incidence of CMV, but not significantly ( $P = 0.26, 0.15, \text{ and } 0.16$ , respectively) (Fig. 6a-b).




Figure 6. Kaplan-Meier survival curves of recipient clinical features and donor cytokine polymorphisms affecting CMV incidence. a) Long prophylaxis compared to no or short prophylaxis, b) immunotherapy (black) and delayed graft function (DGF, grey), c) donor *IL10* -1082 genotype, and d) donor *IFNG* +874 genotype. Copyright © 2006 Elsevier B.V. All rights reserved <sup>307</sup>.

Recipient and donor cytokine polymorphisms were compared by Kaplan-Meier analysis. The analysis was done between patients with and without CMV diagnosis, at genotype and/or phenotype level. The donor *IL10* -1082AA genotype decreased the incidence of CMV ( $P = 0.031$ ) (Fig. 6c). The *IL10* -1082AA genotype has been associated with low IL10 cytokine production <sup>308</sup>. CMV incidences were three out of 20 (15%) in AA and 21 out of 51 (41%) in AG/GG genotypes. The median time to CMV diagnosis was 83 days for AA and 45 for AG or GG genotypes (Mann-Whitney  $p$  for trend = 0.072). Further, none of the recipients receiving a graft from a donor with *IL10* -819TT/-592AA genotype (which is also associated with a phenotype of low IL10 cytokine expression) developed CMV. However, since there were only five such patients the effect did not reach statistical significance ( $P$  for trend = 0.051) and would not have been clinically relevant.

Donor *IL6* -174CG/GG and donor *IFNG* +874TT genotypes (both associated with high cytokine expression phenotype) <sup>308</sup> were both slightly less common, but not significantly, in cases developing CMV ( $P = 0.33, 0.17$ , respectively) (Fig. 6d). The 66 available recipient genotypes did not associate with CMV incidence.

Multivariate analysis with the Cox proportional hazards model gave no other variable except donor *IL10* -1082AA genotype, which was alone significant with respect to reduced incidence of CMV (HR 0.3, 95% CI 0.09 – 0.96,  $P = 0.043$ ).

Human IL10 is an immunosuppressive cytokine which suppresses cytokine and chemokine production by macrophages, T-helper cells, NK cells and peripheral blood mononuclear cells <sup>309</sup>. CMV encodes a homologue of human IL10, which the virus uses to evade immune surveillance <sup>310</sup>. The homologue probably allows the virus to survive in infected cells, replicate and develop a full infection <sup>311</sup>. Accordingly, a genetically CMV susceptible mouse strain produced higher quantities of IL10 leading to the Th2 type of immunoresponse compared to a mouse strain genetically resistant to CMV <sup>312</sup>. Thus, in the viral microenvironment, high quantities of IL10 probably augment the spread of infection. In our study, the IL10 low production genotype in donors was found to protect against CMV reactivation. It seems possible that CMV infected cells in donor organs produce extra IL10 with an effect similar to the viral homologue.

On the other hand, Conti et al. reported that systemic production of IL10 by recipient cells stimulated B cell proliferation, antibody secretion and development of cytotoxic T cells <sup>309</sup>. However, these late occurring systemic responses to infection probably limit the extent of the infection and damage, rather than inhibiting the early stages of CMV reactivation. The genetic background of the recipient can be assumed to influence more the systemic response than that occurring locally within the graft with donor background.

The known predisposing factors in kidney allograft recipients for CMV disease are high-dose immunosuppressive protocol, co-morbidity, viral load, and DGF <sup>313,314</sup>. In a large meta-analysis, anti-viral prophylaxis significantly reduced the risk of CMV disease (19 trials, 1981 patients; relative risk 0.42 [95% CI 0.34–0.52]) and infection (17 trials, 1786 patients; 0.61 [0.48–0.77]) <sup>315</sup>. We found only a trend-level association between prophylaxis and reduced CMV incidence, probably due to the relatively small patient (71) population.

In conclusion, we found that donor *IL10* -1082AA genotype was associated with a reduced incidence of CMV in CMV-seronegative recipients of allografts from seropositive donors. Further and more extensive investigations may confirm the clinical relevance of this risk



factor. Moreover, the genetic background of the donor may help to assess post-Tx risks in kidney allograft recipients.

### **6.3 Genetic variation in thrombosis-associated or cytokine gene polymorphism did not predispose to thrombosis (IV)**

In this study there were 38 (4.9%) recipients diagnosed with venous thrombosis and/or pulmonary embolism. We genotyped *F5* G1691A, *F5* A4070G, *F2* G20210A, *F13A1* G204T, *PROC* T8853G, *TFPI* C536T, *MTHFR* C677T, *TNF* G(-308)A, *IL10* A(-1082)G, *IL10* C(-592)A, and *IL6* C(-174)G, totalling 11 SNPs in nine genes. Of the non-genetic factors, patient age over 50 years increased the risk of suffering a thrombotic complication (OR 2.8, 95% CI 1.3 - 5.8). The SNPs studied in the recipients or donors were not significantly associated with any of the studied outcomes after correcting for multiple testing.

Increased risk for thrombosis in renal transplant recipients and association with *F5* G1691A has been found in two reports<sup>170,173</sup>. These studies had 300 and 202 recipients, and 26% and 11% incidence of thrombosis, respectively. Sample size was moderate in both, but by current standards the thrombosis incidence was exceptionally high, which may augment the risk associated with *F5* G1691A. A negative association was found in three reported studies involving 109, 394, and 509 recipients (and also 457 donors in the last study) with 27%, 6%, and 8% incidences of thrombosis, respectively<sup>172,174,178</sup>. The first two negative studies probably did not have enough statistical power to detect positive association and in the last study all the recipients had heparin prophylaxis after surgery, which probably prevented all renal vein thromboses and immobility-based thromboses.

The effect of *F5* G1691A mutation (FVL) has been well established in thrombosis patients and their relatives to increase the risk of thrombosis by seven- to 80-fold, whether heterozygous or homozygous for the mutation<sup>316</sup>. ESRD patients with increased susceptibility to thrombosis are commonly identified during haemodialysis with problems of blood clotting in dialysis catheters. However, whether anticoagulation medication is continued after Tx depends on the centre, in the absence of uniform international consensus<sup>88</sup>.

Pherwani et al. reported negative *F2* G20210A mutation association with thrombosis in 562 renal transplant recipients and 457 donors<sup>178</sup>. In their study all recipients had heparin prophylaxis for thrombosis, which may modify the negative genetic association. Even though *F2* G20210A



mutation may not specifically increase the risk of thrombosis in renal Tx recipients, it may decrease GS by association with other complications like vascular rejection <sup>88</sup>. However, *F2* G20210A mutation heterozygosity is associated with a 2.8-fold increased risk of thrombosis compared with non-mutation carriers <sup>316</sup>.

Apart from the present report (IV), there are no kidney Tx studies regarding the association between *MTHFR* C677T polymorphism and thrombosis. However, a recent meta-analysis of published epidemiological studies of 8364 first-time or recurrent thrombosis cases and 12 468 controls found that the 677TT genotype was associated with a 20% higher risk of thrombosis compared with the 677CC genotype. This may be modified by the nutritional intake of folate and riboflavin, which can cause contradictory association results between populations with different diets <sup>317</sup>. Finnish kidney Tx patients often take multivitamins including low doses of folate and riboflavin, which may in part explain our negative results if low doses are considered to be effective.

### **6.3.1 Thrombosis-associated or cytokine gene polymorphisms did not predispose to infarction (IV)**

In this study there were 48 recipients with cerebral infarcts (35.4%), with myocardial infarcts (62.5%), and with kidney infarcts (2.1%). Non-genetic or genetic factors of the recipients and donors did not associate with infarcts.

These results are in accordance with studies that did not find association between infarction and *IL6* G(-174)C <sup>318,319</sup>, or *F5* A4070G <sup>320</sup>, or *F5* G1691A <sup>319</sup>, or *F13A1* G204T, *IL10* A(-1082)G, *IL10* C(-592)A, *MTHFR* C677T and *F2* G20210A <sup>319</sup>. There is only one published study on kidney Tx patients and it did not report association between *F5* G1691A and myocardial infarction <sup>170</sup>. Studies finding association between infarction and *F5* G1691A <sup>321</sup>, or *MTHFR* C677T <sup>183</sup> did not study kidney Tx outcomes but myocardial infarction among other cardiovascular diseases. In one genome-wide association study LTA associated with infarction in a Japanese population <sup>322</sup> but not in a replication study also among Japanese <sup>323</sup>. This non-replication may be due to different diagnostic criteria and lack of statistical power <sup>324</sup>.

### **6.3.2 Thrombosis-associated or cytokine gene polymorphisms were not associated with graft survival**

Graft loss within the first year after Tx was due to AR, thrombosis or infarct in 28 (62%) out of 45 losses (other graft losses were due to nine patient deaths and eight other causes, e.g. primary disease relapse). We genotyped *F5* G1691A, *F5* A4070G, *F2* G20210A, *F13A1* G204T, *PROC* T8853G, *TFPI* C536T, *MTHFR* C677T, *TNF* G(-308)A, *IL10* A(-1082)G, *IL10* C(-592)A, and *IL6* C(-174)G, totalling 11 SNPs from nine genes. The one-year GS was not significantly influenced by the studied genetic or non-genetic factors of recipients or donors analysed by the bivariate analyses.

Recently, one large multicentre study compared the association between the GS of 676 cadaver kidney first or 651 retransplants and *F5* G1691A, *F2* G20210A or *MTHFR* C677T polymorphisms. In this study *F2* G20210A associated with the three-year survival of first transplants<sup>180</sup>. We analysed our data separately for the first and retransplant subgroups but did not find an association with GS. This may have been due to our small study size.

In addition, FVL was reported to associate with GS in a study of 109 kidney recipients with a high incidence (27%) of vascular rejection<sup>172</sup>. In our study the vascular rejection incidence was 2%, which probably affected our negative finding. Our results are similar to three other studies which were also unable to find association between GS and FVL<sup>175,177,178</sup>.

Two further studies reported association between *F2* G20210A and GS<sup>175,182</sup>. The first had a 13% retransplant rate compared to our rate of 1%. The latter study was a prospective investigation with high AR (44%, ours 18%) and acute vascular rejection (28%, ours 2%) incidences, suggesting under-immunosuppression or over-selection of patients with additional risk factors. A study reporting negative association between *F2* and GS<sup>178</sup> involved the use of heparin post-Tx thrombosis prophylaxis which may have reduced the incidence of fatal complications post-Tx. In our study most patients were on acetylsalicylic acid, which may have reduced graft thrombosis and cardiac complication incidences leading to graft loss.

Although several studies have reported an association between *MTHFR* C677T and homocysteine or lipid levels<sup>184-192</sup>, none has reported a positive association between *MTHFR* C677T and GS<sup>175,193,194,196</sup>. Most study patients take multivitamins including low doses of folic acid and riboflavin, which may reduce homocysteine levels irrespective

of *MTHFR* C677T genotype status. The *MTHFR* C677T genotype may have an influence on GS through increased (OR = 1.2) susceptibility to cardiovascular complications <sup>325</sup>, probably warranting large prospective studies including diet and multivitamin use information.

Cytokine gene polymorphisms were not associated with GS in our study. Similarly, several studies have reported negative associations between *TNF* G(-308)A, *IL10* G(-1082)A, C(-592)A, *IL6* G(-174)C and GS <sup>96,100,116,117,141,326</sup>. Mytilineos et al. reported an association between 59 retransplanted *TNF* -308AA carriers and GS <sup>117</sup>, which we were not able to study as we did not have retransplanted *TNF* -308AA carriers in the study population.

#### **6.4 Gene expression markers showed similar time-related variance during hospital stay in control patients (III)**

The aim of this study was to determine whether analysis of whole blood gene expression of lymphocyte marker molecules would offer a robust means to diagnose AR after kidney Tx. If clinically useful, such a method would provide a non-invasive, easy, and rapidly performed test that could be routinely applied to detect rejection at an early phase before permanent injury has occurred. In particular, collection of whole blood into tubes with RNA stabilising solution that can be stored at room temperature would allow easy adaptation to routine hospital sample collection.

We decided to test the relevance of this method by investigating eight candidate molecular markers: perforin 1 (Per), fas ligand (FL), granzyme B (GB), granulysin (Gra), CD40 ligand (CD154), inducible T cell co-stimulator (ICOS), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), and programmed cell death 1 (PD-1). Per, FL, GB and Gra are lymphocyte cytotoxic molecules that have a clear role in the molecular process of allograft rejection and that have previously been suggested to have diagnostic value <sup>327</sup>. In addition, we hypothesized that the gene expression quantities of co-stimulatory molecules CD154, ICOS, CTLA4, and PD-1 associated with T-cell activation would be significantly altered at a time of an AR episode and therefore be able to distinguish rejection from non-rejection samples. These were chosen based on a literature search.

Control patients were studied in order to determine the changes in gene expression associated with pre- and post-Tx course without rejection. The relative quantity of four costimulatory (ICOS, CD154,

CTLA4 and PD-1) and four cytotoxic (FL, Gra, GB and Per) genes followed the same general pattern after Tx. There was a rapid decrease of gene expression by approximately 50% between day 0 and day 1, followed by a slow increase so that by day 21 the levels were again close to those on day 0 (Fig. 7).




Figure 7. The relative gene expression quantities of studied genes relative to the d0 sample of control patients. Error bars represent the standard deviation of replicate wells normalised to endogenous control gene and calibrator. Med denotes median. Copyright © 2007 Lippincott Williams & Wilkins. All rights reserved <sup>289</sup>.

The two studies of serial analysis of whole blood gene expression quantities after Tx are in accordance with ours <sup>251,290</sup>. One study reported lower quantities of granulysin on post-Tx day 1 than before Tx and higher levels on day 7 than on day 1 <sup>290</sup>, and the other noted up-regulation of Per and GB in eight paediatric renal allograft recipients between day 1 and day 30 in peripheral blood leukocyte samples <sup>251</sup>. It seems likely that the early decrease in whole blood gene expression quantities reflects the massive infiltration of T-cells expressing the studied markers to the transplanted kidney at the time of Tx <sup>328</sup>, which is gradually reversed as time passes and immunosuppressive medication stabilises the situation.

## 6.5 The expression of two genes was different in rejection patients than in control patients (III)

In order to determine whether AR episodes were associated with changes in gene expression, we compared 25 rejection and 15 control patients. The gene expression quantities of cytotoxic molecules were lower in the rejection patients than in the controls, although the differences were not statistically significant (Fig. 8). The gene expression quantities of the costimulatory molecules ICOS and CD154 were significantly lower




Figure 8. The relative gene expression quantity of eight studied genes compared between individual control patient medians and rejection patient samples from post-Tx day 8. The combined box/whisker and dot plots show 10%, 25%, 50% (median), 75%, and 90% percentiles, all the data points of individual outliers are between 90% and 100% percentiles. C, control patients; AR, rejection patients. Copyright © 2007 Lippincott Williams & Wilkins. All rights reserved <sup>289</sup>.

in rejection patients ( $P < 0.001$ , both). The gene expression quantity of the costimulatory molecules CTLA4 and PD-1 showed no statistically significant differences between rejection patients and controls (Fig. 8).

Our study design did not allow us to serially analyse samples taken from the same patient until rejection occurred. In the protocol, samples of individual patients are calibrated with their own pre-Tx sample and in the constellation Per and GB gene expression has been found to increase before the onset of an AR episode<sup>283,284</sup>. In a similar investigation, CD154 and ICOS might be better to differentiate rejection from non-rejection patients.

Mechanistically, it seems likely that the decreases in CD154 and ICOS gene expression in whole blood we observed during rejection and/or other complications are due to lymphocytes expressing the molecules migrating to the allograft during injury. CD154 and ICOS gene expression increases in renal allograft biopsies of recipients with subclinical or acute cellular rejection<sup>268</sup>, and FL, Gra, GB, Per, CD154, ICOS, CTLA4 and PD-1 gene expression increases in SCR and AR biopsy material compared to stable allograft biopsies<sup>267,268</sup>. Similarly, in kidney biopsies CD154 expression increases more during AR episodes than during other types of renal dysfunction (cyclosporine toxicity, acute tubular necrosis, recurrence of primary disease, vascular complication or chronic rejection)<sup>329</sup>.

The comparison of our results with data reported by other investigators is challenging since there are differences in patient population, immunosuppression, sampling schedule, sample type, sample handling and the analysis itself<sup>198,330-332</sup>. Possibly the single most important technical difference between our study and previous investigations is that we used a tube pre-filled with RNA-stabilising solution to draw samples into. To our knowledge there are no previously published results utilising this particular method in kidney transplant recipients, making direct comparison of results impossible. The whole blood sample drawn into the tubes did not give the same transcriptional profile as kidney biopsy, urine cells, isolated blood cells or whole blood in studies utilising different technology, probably due to the different sample processing method. In particular we were unable to detect the significant increase in the expression of cytotoxic gene markers that is usually reported to occur during an AR episode<sup>333</sup>.

## 6.6 Rejection patients differed from non-rejection patients with regard to one gene expression marker (III)

The 25 rejection patients were compared to the 10 kidney biopsied non-rejection patients (RS). The gene expression quantities of all cytotoxic molecules (except FL, which did not differ) were lower in rejection patients; however the differences did not reach statistical significance (Fig. 9). The gene expression quantities of costimulatory molecules




Figure 9. The relative gene expression of the studied genes compared between rejection and non-rejection patients. The combined box/whisker and dot plots show 10%, 25%, 50% (median), 75%, and 90% percentiles; all the data points of individual outliers are between the 0% and 10% or 90% and 100% percentiles. AR, rejection patients; RS, non-rejection patients. Copyright © 2007 Lippincott Williams & Wilkins. All rights reserved <sup>289</sup>.

CD154 and ICOS were also lower in rejection patients, but only CD154 reached statistical significance ( $P = 0.028$ ). The gene expression quantities of CTLA4 or PD-1 did not differ significantly (Fig. 9).

In conclusion, we were unable to determine that the use of whole blood gene expression of lymphocyte molecules would be feasible for the clinical diagnostics of acute kidney allograft rejection. We discovered that the whole blood gene expression of costimulatory molecules CD154 and ICOS reasonably robustly differentiated rejection patients from control patients. However, the clinical use of the analysis is limited by poor capability to differentiate rejection patients from those with other complications causing a suspicion of clinical rejection.

## **6.7 Candidate gene expression markers did not differ between patients with subclinical rejection and control patients (V)**

The aim of this study was to analyse gene expression differences between SCR and non-rejection patients by microarray and RT-QPCR in whole blood samples, in order to determine whether the approach could be clinically useful as a non-invasive method to diagnose SCR in kidney Tx. We measured the relative gene quantities of CD154 and ICOS from whole blood samples taken three and/or six months after Tx. We analysed 31 samples taken at three months. Thirteen of these were from patients whose kidney biopsy was classified as SCR. Eighteen of the samples were from patients with biopsies showing no rejection signs.

At three months, the whole blood CD154 and ICOS expressions in patients with or without SCR were not significantly different (medians 1.16 vs 1.25 and 1.61 vs 1.95 for CD154 and ICOS, respectively) (Fig. 10). In addition, the three- and six-month samples showed no significant expression change in either CD154 or ICOS regardless of whether the patient had SCR at three months or not (medians 1.25 vs 1.67 and 1.50 vs 1.87 for CD154 and ICOS, respectively).

We collected blood samples into tubes pre-filled with a RNA-stabilising solution. These tubes may circumvent the problem of false gene expression results caused by the degradation of RNA or activation of blood cells during collection, transportation, storage and batch processing of samples<sup>334-337</sup>. However, whole blood sample results may be different to kidney biopsy or urine sample results as the different source samples may not carry the same qualitative and/or quantitative biomarker information<sup>331</sup>.






Figure 10. The relative gene expression quantities of CD154, ICOS, and CD3E in 13 subclinical rejection and 17 normal samples taken at the three-month clinical visit. N, normal patients; SCR, subclinical rejection patients.

We were unable to separate patients with or without SCR with CD154 and ICOS expression in whole blood samples, although they separated adult kidney Tx with or without clinical rejection in our study III. Subtle gene expression changes and/or different molecules involved in subclinical compared to clinical rejection episodes may explain the difference in results.

## 6.8 Gene expression markers of the low-density array were unable to identify patients with subclinical rejection (III)

We performed the LDA of immune genes from five kidney biopsy-proven normal, five SCR samples, and one calibrator sample from a healthy untransplanted volunteer. Of the 96 genes in the array, at least three normal, three SCR samples and the calibrator sample expressed 57 genes. The only significantly differently expressed ( $P = 0.04$ ) gene was CD3E (CD3e molecule, epsilon [CD3-TCR complex]), which was slightly decreased in samples with SCR compared to samples without SCR (medians 1.12 vs. 2.65, respectively). For array finding validation, we measured with single RT-QPCR reactions the relative expression of CD3E

from the above samples and a further 12 normal and seven SCR three-month samples. The CD3E expression was not statistically significantly decreased in samples with SCR compared to samples without SCR (medians 1.66 to 2.25, respectively) (Fig. 10).

Since we did not find association between gene expression of CD154 or ICOS and SCR, we examined in LDA format the expression of immunological genes, including several of the candidate markers for rejection proposed by other investigators <sup>268</sup>. Although CD3E expression was significantly different between patients with and without SCR in LDA, we were unable to observe this difference in a larger number of samples, probably due to heterogeneous expression. A decreased CD3E molecule amount in peripheral blood lymphocytes associates in kidney Tx with long-term surviving kidneys <sup>338</sup>, while increased CD3E gene expression associates with AR <sup>277</sup>.

## **6.9 A robust biomarker specific for subclinical rejection could not be identified in whole genome microarray analysis (III)**

We performed two separate hybridisations. The first hybridisation consisted of eight paired whole blood samples of four patients. The pairwise samples came from patients with SCR in the three-month protocol biopsy (Banff grade 1A) and six-month protocol biopsy with normal Banff grade. After GCOS analysis, we further analysed all the genes with at least two-fold average change. There were 26 probe sets representing 20 genes. From these, we quantified with RT-QPCR six genes (BCL2L, BAG, CGI69, NAPA, FKBP8, PCGF5) with the largest fold change. However, none of the genes expressed significantly differently in RT-QPCR.

In the second hybridisation, we processed four whole blood samples from patients with a normal three-month protocol biopsy. With GCOS analysis we compared these samples to those of four patients with a SCR in their three-month biopsy from first hybridisation. From these comparisons, we listed all the genes that were common to all the samples with significant change between SCR and normal samples. We found 29 shared probe sets representing 27 genes. From these, we further analysed 11 genes (MALAT1, TRA2A, IRF2BP2, MARCKS, TNPO1, SLC8A1, HIPK1, CALR, IQGAP1, DICER1 and LYPLA1) with over two-fold change in most patients or the largest average fold change. We performed RT-QPCR analysis from the samples that were in the microarray analysis and an additional 19 three-month samples (11 from

patients without and eight from patients with SCR). However, we could not find differences between patient groups with RT-QPCR as expression was heterogeneous and overlapping between normal and SCR patients.

As we recognised that many of the human genes involved in SCR were not present in the limited, immunologically oriented LDA, we performed a whole genome array to determine whether, with this approach, we could identify surrogate SCR marker genes. Since RNA isolated from the whole blood contains excessive amounts of globin mRNA, which may interfere with the microarray hybridisation <sup>339</sup>, we performed globin reduction before hybridisation.

We found several differently expressed genes when we compared SCR with normal samples or samples taken after the clearance of SCR. However, the average expression fold changes were low and differences between samples large, suggesting that the genetic pathways contributing to SCR are heterogeneous. Further, because in the clinical setting SCR manifests itself solely in the graft, analysing whole blood samples drawn from peripheral veins may not fully reflect the graft processes. After validation with RT-QPCR from additional samples, none of the genes separated SCR and normal samples due to overlapping expression between groups.

In one Tx study, Horwitz et al. reported using the tubes by same manufacturer as us in their investigation of AR-induced gene expression in heart Tx <sup>340</sup>. In their study, minor fold changes of expression associate with AR. From their data, only one gene (Ubiquinol-cytochrome C reductase binding protein (UQCRB) associated with AR with over two-fold change, which was our criterion. None of our kidney Tx patient samples expressed the UQCRB, and it may be distinctive to heart Tx.

In conclusion, we discovered only subtle changes in peripheral whole blood gene expression profiles in paediatric renal Tx patients with or without SCR. Although the genes of the immune system associate with clinically suspected rejection episodes, these were not significant in our investigation of patients with SCR. Our relatively small series suggests that whole blood analysis is not able to find robust gene expression biomarkers for SCR. Further studies in larger populations may reveal whether any of the genes with small changes in expression in our study might provide a supporting diagnostic method.

## STRATEGIES FOR THE FUTURE

As renal Tx treatment protocols have evolved to overcome the frequent rejection episodes of the early days of Tx, the aim of improving therapies currently emphasizes individualised immunotherapy to lengthen the graft and patient survival as well as to improve the recipient's quality of life. Excessively potent immunosuppression increases the risk of infections, cancer and nephrotoxicity, while insufficient immunosuppression results in rejection.

One approach towards optimal immunosuppression is to regularly monitor biomarkers reflecting processes leading to rejection. However, as every patient-graft pair is individual in immunological responses, no single biomarker is relevant for all. The current clinical monitoring of graft function is largely based on measuring serum creatinine/cystatin-c. This lacks sensitivity and specificity and may result in too late recognition of rejection or nephrotoxicity. The frequent use of core needle biopsy is limited by its cost and invasive nature. Immunosuppression is monitored also by pharmacokinetics measuring concentration of drugs in blood <sup>341</sup>. In addition functional assays can be performed - a new pharmacodynamic method detects cell-mediated immunity by measuring the concentration of ATP from whole blood CD4 cells following stimulation <sup>342</sup>. Constant search and development continues to find other noninvasive tools needed.

Currently tested monitoring sources include cells, mRNA and proteins in urine or peripheral blood. Two utilized strategies are to monitor alloimmune responses in the graft or global changes in immune responses of the host. Alloimmune monitoring takes place before and after Tx by measuring the reactivity of recipient HLA antibodies to donor cells or HLA antigens in beads. These antibody-based tools have been more successful than T cell-based tests for predicting rejection. However, the two strategies are successful only when an alloimmune response takes place also in circulation and not only in the graft. The second strategy, to monitor global changes in immune response, faces the problem of separating rejection and infection mediated immune responses from each other. Routinely used creatinine measurement detects mainly glomerular injury but less tubulointerstitial injury. Tubular markers have been found from urine that may separate ischemia from AR, chronic rejection, infection and nephrotoxicity, although not separating the latter from each other. This leads to the conclusion that whereas a single

biomarker for diagnosing any of the entities may never be found, a combination of many biomarkers may distinguish compartments and reveal the reason for injury.

A new emerging field is global analysis of different biomolecule classes that can be studied by proteomics, glycomics, lipidomics or metabolomics. However, as these scientific disciplines are much more complex than genomics, a large amount of work remains to be done simply to characterise the different molecules before even studying their performance as biomarkers. It is expected that a significant number of potential novel biomarkers will be found. However, only a few can be expected to be validated in prospective studies and enter clinical practice.<sup>343</sup>.

## **CONCLUSIONS**

This research demonstrates the lack of robust polymorphisms among studied SNPs or biomarkers in investigated genes that could be included in routine analysis in a clinical laboratory. Even though weak associations were found, their predictive value was insufficient for use in clinical decision-making. However, as future technology advances are likely to make large-scale genetic tests affordable, data on several hundreds of genetic markers may be combined and used in personalized patient treatment<sup>344</sup>.

## ACKNOWLEDGEMENTS

This work was carried out at the Finnish Red Cross Blood Service in Helsinki during 2002 - 2007. I thank Docent Jukka Rautonen, Director of the Institute, for providing me research and working facilities. The financial support of Finnish Red Cross Blood Service EVO grant and the University of Helsinki are acknowledged.

I thank my supervisors Docents Jarmo Laine, MD, PhD and Jukka Partanen, PhD.

Docents Maija Wessman, PhD and Petri Koskinen, MD, PhD are gratefully acknowledged for revising the thesis, for their helpful comments and for their commitment of their time to this work.


For the invaluable co-operation I thank Docent Kaija Salmela, MD, PhD, Docent Lauri Kyllönen, MD, PhD, Irma Matinlauri, MD, PhD, Professor Christer Holmberg, MD, PhD, Paula Seikku, MD, MSc (Physics) and Docent Taina Jaatinen, PhD. Statistical expertise of Virva Jäntti, MSc, Hanna Salo, MSc, and Lauri Nikkinen, MSc, are acknowledged.

For expert language consultancy I thank Richard Burton, MA, for expert library services I thank Marja-Leena Hyvönen, MA and Mrs. Maija Ekholm and for expert administrative services I thank Mrs. Pirjo Nick.

My warmest thanks go to all present and former members of Research and Development and Tissue Typing Departments of the Finnish Red Cross Blood Service and Transplantation Office of the Helsinki University Hospital.

Thank you Janne.

Helsinki, December 2007



## REFERENCES

1. O'Callaghan CA. Clinical features of kidney disease. In: The renal system at a glance. Ed. O'Callaghan CA. Blackwell Pub, Malden, Mass 2006.
2. Dew MA, Switzer GE, Goycoolea JM, et al. Does transplantation produce quality of life benefits? A quantitative analysis of the literature. *Transplantation* 1997;64:1261-1273.
3. Schieppati A & Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. *Kidney Int Suppl* 2005;S7-S10.
4. Guild WR, Harrison JH, Merrill JP & Murray J. Successful homotransplantation of the kidney in an identical twin. *Trans Am Clin Climatol Assoc* 1955;67:167-173.
5. Kuhlback B & Lindström BL. [Renal transplantation]. *Duodecim* 1967;83:968-976.
6. Salmela K, Kyllönen L, Eklund B, et al. Thirty years of renal transplantation in Helsinki. *Clin Transpl* 1994;Chapter 20:219-228.
7. Kyllönen LE, Pukkala E & Eklund B. Cancer incidence in a kidney-transplanted population. *Transpl Int* 1994;7 Suppl 1:S350-S352.
8. Salmela KT & Kyllönen LE. Two decades of experience with cyclosporine in renal transplantation in Helsinki. *Transplant Proc* 2004;36:94S-98S.
9. Kyllönen L, Kahu J, Kyllönen L & Salmela K. Kidney transplantation from 1119 deceased donors in Finland, 1991 to 2003: impact of donor factors. *Transplant Proc* 2005;37:3248-3252.
10. Kahan BD. Individuality: the barrier to optimal immunosuppression. *Nat Rev Immunol* 2003;3:831-838.
11. Yabu JM & Vincenti F. Novel immunosuppression: small molecules and biologics. *Semin Nephrol* 2007;27:479-486.
12. Marroquin CE, Edwards EB, Collins BH, Desai DM, Tuttle-Newhall JE & Kuo PC. Half-life analysis of pancreas and kidney transplants. *Transplantation* 2005;80:272-275.
13. Patrakka J, Kestilä M, Wartiovaara J, et al. Congenital nephrotic syndrome (NPHS1): features resulting from different mutations in Finnish patients. *Kidney Int* 2000;58:972-980.
14. Jalanko H. Congenital nephrotic syndrome. *Pediatr Nephrol* 2007;[Epub ahead of print].
15. Witas A, Nordfors L, Lindholm B & Stenvinkel P. Use of single-nucleotide polymorphisms in the search for genetic modifiers of the uremic phenotype. *J Ren Nutr* 2007;17:17-22.
16. Axelsson J, Devuyst O, Nordfors L, Heimbürger O, Stenvinkel P & Lindholm B. Place of genotyping and phenotyping in understanding and potentially modifying outcomes in peritoneal dialysis patients. *Kidney Int Suppl* 2006;S138-S145.

17. Zoccali C, Testa A, Spoto B, Tripepi G & Mallamaci F. Mendelian randomization: a new approach to studying epidemiology in ESRD. *Am J Kidney Dis* 2006;47:332-341.
18. Chow KM, Wong TY & Li PK. Genetics of common progressive renal disease. *Kidney Int Suppl* 2005;67:S41-S45.
19. Freedman BI, Volkova NV, Satko SG, et al. Population-based screening for family history of end-stage renal disease among incident dialysis patients. *Am J Nephrol* 2005;25:529-535.
20. Moczulski DK, Rogus JJ, Antonellis A, Warram JH & Krolewski AS. Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: results of novel discordant sib-pair analysis. *Diabetes* 1998;47:1164-1169.
21. Österholm AM, He B, Pitkaniemi J, et al. Genome-wide scan for type 1 diabetic nephropathy in the Finnish population reveals suggestive linkage to a single locus on chromosome 3q. *Kidney Int* 2007;71:140-145.
22. Bowden DW, Colicigno CJ, Langefeld CD, et al. A genome scan for diabetic nephropathy in African Americans. *Kidney Int* 2004;66:1517-1526.
23. Vionnet N, Tregouet D, Kazeem G, et al. Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: strongest evidence for association with a variant in the promoter region of the adiponectin gene. *Diabetes* 2006;55:3166-3174.
24. Iyengar SK, Abboud HE, Goddard KA, et al. Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND). *Diabetes* 2007;56:1577-1585.
25. Vardarli I, Baier LJ, Hanson RL, et al. Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. *Kidney Int* 2002;62:2176-2183.
26. Frojdo S, Sjolind L, Parkkonen M, et al. Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy. *Diabetologia* 2005;48:2278-2281.
27. Joss N, Jardine A, Gaffney D & Boulton-Jones JM. Influence of apolipoprotein E genotype on progression of diabetic nephropathy. *Nephron Exp Nephrol* 2005;101:e127-e133.
28. Bahr C, Schon S, Kuhn J, et al. Novel sequence variants in the human xylosyltransferase I gene and their role in diabetic nephropathy. *Diabet Med* 2006;23:681-684.
29. Mollsten A, Wessman M, Svensson M, et al. Glu298Asp and NOS4ab polymorphisms in diabetic nephropathy. *Ann Med* 2006;38:522-528.
30. Mollsten A, Marklund SL, Wessman M, et al. A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. *Diabetes* 2007;56:265-269.
31. Freedman BI, Bostrom M, Daeihagh P & Bowden DW. Genetic factors in diabetic nephropathy. *Clin J Am Soc Nephrol* 2007;2:1306-1316.
32. Tanaka N & Babazono T. Assessing genetic susceptibility to diabetic nephropathy. *Nephrology (Carlton)* 2005;10 Suppl:S17-S21.



33. Trowsdale J. HLA genomics in the third millennium. *Curr Opin Immunol* 2005;17:498-504.
34. Klein J & Sato A. The HLA system. First of two parts. *N Engl J Med* 2000;343:702-709.
35. Hauptmann G & Bahram S. Genetics of the central MHC. *Curr Opin Immunol* 2004;16:668-672.
36. Beck S & Trowsdale J. The human major histocompatibility complex: lessons from the DNA sequence. *Annu Rev Genomics Hum Genet* 2000;1:117-137.
37. Bugawan TL, Klitz W, Blair A & Erlich HA. High-resolution HLA class I typing in the CEPH families: analysis of linkage disequilibrium among HLA loci. *Tissue Antigens* 2000;56:392-404.
38. Price P, Witt C, Allcock R, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. *Immunol Rev* 1999;167:257-274.
39. Dorak MT, Shao W, Machulla HK, et al. Conserved extended haplotypes of the major histocompatibility complex: further characterization. *Genes Immun* 2006;7:450-467.
40. Van Kaer L. Major histocompatibility complex class I-restricted antigen processing and presentation. *Tissue Antigens* 2002;60:1-9.
41. Saveanu L, Carroll O, Hassainya Y & van Endert P. Complexity, contradictions, and conundrums: studying post-proteasomal proteolysis in HLA class I antigen presentation. *Immunol Rev* 2005;207:42-59.
42. Li P, Gregg JL, Wang N, et al. Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing. *Immunol Rev* 2005;207:206-217.
43. Davis-Harrison RL, Insaiddoo FK & Baker BM. T cell receptor binding transition states and recognition of peptide/MHC. *Biochemistry* 2007;46:1840-1850.
44. Borg NA, Ely LK, Beddoe T, et al. The CDR3 regions of an immunodominant T cell receptor dictate the 'energetic landscape' of peptide-MHC recognition. *Nat Immunol* 2005;6:171-180.
45. Chaplin DD. 1. Overview of the immune response. *J Allergy Clin Immunol* 2003;111:S442-S459.
46. Bolin DR, Swain AL, Sarabu R, et al. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. *J Med Chem* 2000;43:2135-2148.
47. Gaspar R, Jr., Bagossi P, Bene L, et al. Clustering of class I HLA oligomers with CD8 and TCR: three-dimensional models based on fluorescence resonance energy transfer and crystallographic data. *J Immunol* 2001;166:5078-5086.
48. Unanue ER. Perspective on antigen processing and presentation. *Immunol Rev* 2002;185:86-102.
49. Doxiadis II, Smits JM, Persijn GG, Frei U & Claas FH. It takes six to boogie: allocating cadaver kidneys in Eurotransplant. *Transplantation* 2004;77:615-617.

50. Opelz G & Dohler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. *Transplantation* 2007;84:137-143.
51. Takemoto S, Port FK, Claas FH & Duquesnoy RJ. HLA matching for kidney transplantation. *Hum Immunol* 2004;65:1489-1505.
52. Kyllönen L, Salmela K & Matinlauri I. [Is tissue typing unnecessary for kidney transplantation?]. *Duodecim* 2005;121:191-193.
53. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. *N Engl J Med* 2002;347:488-496.
54. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. *Am J Transplant* 2004;4:237-243.
55. LaCasce AS. Post-transplant lymphoproliferative disorders. *Oncologist* 2006;11:674-680.
56. Davis CL & Hricik DE. Transplant: immunology and treatment of rejection. *Am J Kidney Dis* 2004;43:1116-1137.
57. Meier-Kriesche HU, Schold JD, Srinivas TR & Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. *Am J Transplant* 2004;4:378-383.
58. Tantravahi J, Womer KL & Kaplan B. Why Hasn't Eliminating Acute Rejection Improved Graft Survival? *Annu Rev Med* 2007;58:369-385.
59. Le Moine A, Goldman M & Abramowicz D. Multiple pathways to allograft rejection. *Transplantation* 2002;73:1373-1381.
60. Sheldon S & Poulton K. HLA typing and its influence on organ transplantation. *Methods Mol Biol* 2006;333:157-174.
61. Simpson E. Minor transplantation antigens: animal models for human host-versus-graft, graft-versus-host, and graft-versus-leukemia reactions. *Transplantation* 1998;65:611-616.
62. Simpson E, Scott D, James E, et al. Minor H antigens: genes and peptides. *Transpl Immunol* 2002;10:115-123.
63. Spierings E, Vermeulen CJ, Vogt MH, et al. Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation. *Lancet* 2003;362:610-615.
64. Schlichting CL, Schareck WD & Weis M. Renal ischemia-reperfusion injury: new implications of dendritic cell-endothelial cell interactions. *Transplant Proc* 2006;38:670-673.
65. Watschinger B. How T cells recognize alloantigen: evidence for two pathways of allorecognition. *Nephrol Dial Transplant* 1995;10:1556-1558.
66. Schmouder RL & Kunkel SL. The cytokine response in renal allograft rejection. *Nephrol Dial Transplant* 1995;10 Suppl 1:36-43.
67. Obata F, Yoshida K, Ohkubo M, et al. Contribution of CD4+ and CD8+ T cells and interferon-gamma to the progress of chronic rejection of kidney allografts: the Th1 response mediates both acute and chronic rejection. *Transpl Immunol* 2005;14:21-25.

68. Barry M & Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. *Nat Rev Immunol* 2002;2:401-409.
69. Ueda N, Kaushal GP & Shah SV. Apoptotic mechanisms in acute renal failure. *Am J Med* 2000;108:403-415.
70. Zeevi A, Girnita A & Duquesnoy R. HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation. *Immunol Res* 2006;36:255-264.
71. Sacks SH & Zhou W. Allograft rejection: effect of local synthesis of complement. *Springer Semin Immunopathol* 2005;27:332-344.
72. Kitchens WH, Uehara S, Chase CM, Colvin RB, Russell PS & Madsen JC. The changing role of natural killer cells in solid organ rejection and tolerance. *Transplantation* 2006;81:811-817.
73. Pelletier RP, Hennessy PK, Adams PW & Orosz CG. High incidence of donor-reactive delayed-type hypersensitivity reactivity in transplant patients. *Am J Transplant* 2002;2:926-933.
74. Sykes M. Immune tolerance: mechanisms and application in clinical transplantation. *J Intern Med* 2007;262:288-310.
75. Izawa A, Sayegh MH & Chandraker A. The antagonism of calcineurin inhibitors and costimulatory blockers: fact or fiction? *Transplant Proc* 2004;36:570S-573S.
76. Ashton-Chess J, Brouard S & Souillou JP. Is clinical tolerance realistic in the next decade? *Transpl Int* 2006;19:539-548.
77. Larosa DF, Rahman AH & Turka LA. The innate immune system in allograft rejection and tolerance. *J Immunol* 2007;178:7503-7509.
78. Halloran PF, Aprile MA, Farewell V, et al. Early function as the principal correlate of graft survival. A multivariate analysis of 200 cadaveric renal transplants treated with a protocol incorporating antilymphocyte globulin and cyclosporine. *Transplantation* 1988;46:223-228.
79. Kyllönen LE & Salmela KT. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study. *Transplantation* 2006;81:1010-1015.
80. Daly PJ, Power RE, Healy DA, Hickey DP, Fitzpatrick JM & Watson RW. Delayed graft function: a dilemma in renal transplantation. *BJU Int* 2005;96:498-501.
81. Quiroga I, McShane P, Koo DD, et al. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. *Nephrol Dial Transplant* 2006;21:1689-1696.
82. Kyllönen LE, Salmela KT, Eklund BH, et al. Long-term results of 1047 cadaveric kidney transplantations with special emphasis on initial graft function and rejection. *Transpl Int* 2000;13:122-128.
83. Perico N, Cattaneo D, Sayegh MH & Remuzzi G. Delayed graft function in kidney transplantation. *Lancet* 2004;364:1814-1827.
84. Koning OH, Ploeg RJ, van Bockel JH, et al. Risk factors for delayed graft function in cadaveric kidney transplantation: a prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. European Multicenter Study Group. *Transplantation* 1997;63:1620-1628.
85. Das A. Cytomegalovirus infection in solid organ transplantation: economic implications. *Pharmacoeconomics* 2003;21:467-475.

86. Opelz G, Dohler B & Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. *Am J Transplant* 2004;4:928-936.
87. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. *Kidney Int* 2004;66:329-337.
88. Irish A. Hypercoagulability in renal transplant recipients : identifying patients at risk of renal allograft thrombosis and evaluating strategies for prevention. *Am J Cardiovasc Drugs* 2004;4:139-149.
89. Kranz B, Vester U, Nadalin S, Paul A, Broelsch CE & Hoyer PF. Outcome after kidney transplantation in children with thrombotic risk factors. *Pediatr Transplant* 2006;10:788-793.
90. Poli D, Zanazzi M, Antonucci E, et al. Renal transplant recipients are at high risk for both symptomatic and asymptomatic deep vein thrombosis. *J Thromb Haemost* 2006;4:988-992.
91. Zanazzi M, Poli D, Antonucci E, et al. Venous thromboembolism in renal transplant recipients: high rate of recurrence. *Transplant Proc* 2005;37:2493-2494.
92. Kang DH, Kang SW, Jeong HJ, Kim YS, Yang CW & Johnson RJ. Transplant graft vasculopathy: an emerging target for prevention and treatment of renal allograft dysfunction. *Yonsei Med J* 2004;45:1053-1058.
93. Humar A & Matas AJ. Surgical complications after kidney transplantation. *Semin Dial* 2005;18:505-510.
94. Wuthrich RP. Factor V Leiden mutation: potential thrombogenic role in renal vein, dialysis graft and transplant vascular thrombosis. *Curr Opin Nephrol Hypertens* 2001;10:409-414.
95. Hutchinson IV, Turner D, Sankaran D, Awad M, Pravica V & Sinnott P. Cytokine genotypes in allograft rejection: guidelines for immunosuppression. *Transplant Proc* 1998;30:3991-3992.
96. Hahn AB, Kasten-Jolly JC, Constantino DM, et al. TNF-alpha, IL-6, IFN-gamma, and IL-10 gene expression polymorphisms and the IL-4 receptor alpha-chain variant Q576R: effects on renal allograft outcome. *Transplantation* 2001;72:660-665.
97. Janeway CA, Travers P, Walport M & Shlomchik M. Cytokines and their receptors. In: *Immunobiology*. Eds. Janeway CA, Travers P, Walport M & Shlomchik M. Garland Science, New York and London 2001.
98. Hutchings A, Guay-Woodford L, Thomas JM, et al. Association of cytokine single nucleotide polymorphisms with B7 costimulatory molecules in kidney allograft recipients. *Pediatr Transplant* 2002;6:69-77.
99. Marder B, Schroppel B & Murphy B. Genetic variability and transplantation. *Curr Opin Urol* 2003;13:81-89.
100. Dmitrienko S, Hoar DI, Balshaw R & Keown PA. Immune response gene polymorphisms in renal transplant recipients. *Transplantation* 2005;80:1773-1782.
101. The human genome. *Science genome map*. *Science* 2001;291:1218.
102. The International HapMap Project. *Nature* 2003;426:789-796.

103. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature* 2007;449:851-861.
104. Willer CJ, Scott LJ, Bonnycastle LL, et al. Tag SNP selection for Finnish individuals based on the CEPH Utah HapMap database. *Genet Epidemiol* 2006;30:180-190.
105. Hattersley AT & McCarthy MI. What makes a good genetic association study? *Lancet* 2005;366:1315-1323.
106. Susal C & Opelz G. Options for immunologic support of renal transplantation through the HLA and immunology laboratories. *Am J Transplant* 2007;7:1450-1456.
107. Davey Smith G., Gwinn M, Ebrahim S, Palmer LJ & Khoury MJ. Make it HuGE: human genome epidemiology reviews, population health, and the IJE. *Int J Epidemiol* 2006;35:507-510.
108. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L & Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. *J Natl Cancer Inst* 2004;96:434-442.
109. Pastinen T & Hudson TJ. Cis-acting regulatory variation in the human genome. *Science* 2004;306:647-650.
110. Wilson AG, Symons JA, McDowell TL, McDevitt HO & Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. *Proc Natl Acad Sci U S A* 1997;94:3195-3199.
111. Abraham LJ & Kroeger KM. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. *J Leukoc Biol* 1999;66:562-566.
112. Sankaran D, Asderakis A, Ashraf S, et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. *Kidney Int* 1999;56:281-288.
113. Pelletier R, Pravica V, Perrey C, et al. Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. *Transplantation* 2000;70:674-680.
114. Poli F, Boschiero L, Giannoni F, et al. Tumour necrosis factor-alpha gene polymorphism: implications in kidney transplantation. *Cytokine* 2000;12:1778-1783.
115. Revirion D, Dussol B, Andre M, Brunet P, Mercier P & Berland Y. TNF-alpha and IL-6 gene polymorphism and rejection in kidney transplantation recipients. *Transplant Proc* 2001;33:350-351.
116. Wramner LG, Norrby J, Hahn-Zoric M, et al. Impaired Kidney Graft Survival is Associated with the TNF-alpha Genotype. *Transplantation* 2004;78:117-121.
117. Mytilineos J, Laux G & Opelz G. Relevance of IL10, TGFbeta1, TNFalpha, and IL4Ralpha Gene Polymorphisms in Kidney Transplantation: A Collaborative Transplant Study Report. *Am J Transplant* 2004;4:1684-1690.
118. Park JY, Park MH, Park H, Ha J, Kim SJ & Ahn C. TNF-alpha and TGF-beta1 gene polymorphisms and renal allograft rejection in Koreans. *Tissue Antigens* 2004;64:660-666.

119. Alakulppi NS, Kyllönen LE, Jäntti VT, et al. Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. *Transplantation* 2004;78:1422-1428.
120. Pawlik A, Domanski L, Rozanski J, et al. IL-2 and TNF-alpha Promoter Polymorphisms in Patients With Acute Kidney Graft Rejection. *Transplant Proc* 2005;37:2041-2043.
121. Tinckam K, Rush D, Hutchinson I, et al. The relative importance of cytokine gene polymorphisms in the development of early and late acute rejection and six-month renal allograft pathology. *Transplantation* 2005;79:836-841.
122. Lacha J, Hribova P, Kotsch K, et al. Effect of cytokines and chemokines (TGF-beta, TNF-alpha, IL-6, IL-10, MCP-1, RANTES) gene polymorphisms in kidney recipients on posttransplantation outcome: influence of donor-recipient match. *Transplant Proc* 2005;37:764-766.
123. Canossi A, Piazza A, Poggi E, et al. Renal Allograft Immune Response Is Influenced by Patient and Donor Cytokine Genotypes. *Transplant Proc* 2007;39:1805-1812.
124. Marshall SE, McLaren AJ, Haldar NA, Bunce M, Morris PJ & Welsh KI. The impact of recipient cytokine genotype on acute rejection after renal transplantation. *Transplantation* 2000;70:1485-1491.
125. George S, Turner D, Reynard M, et al. Significance of cytokine gene polymorphism in renal transplantation. *Transplant Proc* 2001;33:483-484.
126. Cartwright NH, Keen LJ, Demaine AG, et al. A study of cytokine gene polymorphisms and protein secretion in renal transplantation. *Transpl Immunol* 2001;8:237-244.
127. Muller-Steinhardt M, Fricke L, Muller B, Kirchner H & Hartel C. The interleukin-6 -174promoter polymorphism is associated with long-term kidney allograft survival. *Hum Immunol* 2002;63:S13.
128. McDaniel DO, Barber WH, Nguyen C, et al. Combined analysis of cytokine genotype polymorphism and the level of expression with allograft function in African-American renal transplant patients. *Transpl Immunol* 2003;11:107-119.
129. Weimer R, Mytilineos J, Feustel A, et al. Mycophenolate mofetil-based immunosuppression and cytokine genotypes: effects on monokine secretion and antigen presentation in long-term renal transplant recipients. *Transplantation* 2003;75:2090-2099.
130. Uboldi de Capei MU, Dametto E, Fasano ME, et al. Cytokines and chronic rejection: a study in kidney transplant long-term survivors. *Transplantation* 2004;77:548-552.
131. Ligeiro D, Sancho MR, Papoila A, et al. Impact of donor and recipient cytokine genotypes on renal allograft outcome. *Transplant Proc* 2004;36:827-829.
132. Gendzekhadze K, Rivas-Vetencourt P & Montano RF. Risk of adverse post-transplant events after kidney allograft transplantation as predicted by CTLA-4 +49 and TNF-alpha -308 single nucleotide polymorphisms: A preliminary study. *Transpl Immunol* 2006;16:194-199.

133. Azarpira N, Aghdaie M, Geramizadeh B, et al. Cytokine gene polymorphisms in renal transplant recipients. *Exp Clin Transplant* 2006;4:528-531.
134. Poole KL, Gibbs PJ, Evans PR, Sadek SA & Howell WM. Influence of patient and donor cytokine genotypes on renal allograft rejection: evidence from a single centre study. *Transpl Immunol* 2001;8:259-265.
135. Marshall SE, McLaren AJ, McKinney EF, et al. Donor cytokine genotype influences the development of acute rejection after renal transplantation. *Transplantation* 2001;71:469-476.
136. Hoffmann S, Park J, Jacobson LM, et al. Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. *Kidney Int* 2004;66:1686-1693.
137. Hutchinson IV. The role of transforming growth factor-beta in transplant rejection. *Transplant Proc* 1999;31:9S-13S.
138. Awad MR, El Gamel A, Hasleton P, Turner DM, Sinnott PJ & Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. *Transplantation* 1998;66:1014-1020.
139. Amirzargar M, Yavangi M, Basiri A, et al. Genetic Association of Interleukin-4, Interleukin-10, and Transforming Growth Factor-beta Gene Polymorphism With Allograft Function in Renal Transplant Patients. *Transplant Proc* 2007;39:954-957.
140. Suarez A, Castro P, Alonso R, Mozo L & Gutierrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. *Transplantation* 2003;75:711-717.
141. Asderakis A, Sankaran D, Dyer P, et al. Association of polymorphisms in the human interferon-gamma and interleukin-10 gene with acute and chronic kidney transplant outcome: the cytokine effect on transplantation. *Transplantation* 2001;71:674-677.
142. Plathow A, Bicalho MG, Benvenuto R & Contieri FL. Interleukin-10 and acute rejection in renal transplantation. *Transplant Proc* 2003;35:1338-1340.
143. Loucaidou M, Stichbury J, Lee J, et al. Cytokine polymorphisms do not influence acute rejection in renal transplantation under tacrolimus-based immunosuppression. *Transplant Proc* 2005;37:1760-1761.
144. Hoffmann SC, Stanley EM, Darrin CE, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. *Transplantation* 2001;72:1444-1450.
145. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. *J Clin Invest* 1998;102:1369-1376.



146. Pravica V, Perrey C, Stevens A, Lee JH & Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. *Hum Immunol* 2000;61:863-866.
147. Hehlhans T & Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. *Immunology* 2005;115:1-20.
148. Pascher A & Klupp J. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors? *BioDrugs* 2005;19:211-231.
149. Allcock RJ, Windsor L, Gut IG, et al. High-Density SNP genotyping defines 17 distinct haplotypes of the TNF block in the Caucasian population: implications for haplotype tagging. *Hum Mutat* 2004;24:517-525.
150. Medcraft J, Hitman GA, Sachs JA, Whichelow CE, Raafat I & Moore RH. Autoimmune renal disease and tumour necrosis factor beta gene polymorphism. *Clin Nephrol* 1993;40:63-68.
151. Rubtsov YP & Rudensky AY. TGFbeta signalling in control of T-cell-mediated self-reactivity. *Nat Rev Immunol* 2007;7:443-453.
152. Campistol JM, Inigo P, Larios S, Bescos M & Oppenheimer F. Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy. *Nephrol Dial Transplant* 2001;16 Suppl 1:114-116.
153. Mannon RB. Therapeutic targets in the treatment of allograft fibrosis. *Am J Transplant* 2006;6:867-875.
154. Hutchinson IV, Pravica V, Hajeer A & Sinnott PJ. Identification of high and low responders to allografts. *Rev Immunogenet* 1999;1:323-333.
155. Rees LE, Wood NA, Gillespie KM, Lai KN, Gaston K & Mathieson PW. The interleukin-10-1082 G/A polymorphism: allele frequency in different populations and functional significance. *Cell Mol Life Sci* 2002;59:560-569.
156. Song M & Kellum JA. Interleukin-6. *Crit Care Med* 2005;33:S463-S465.
157. Kaden J. IL-6 determination in serum of kidney graft recipients by a new bedside test: its diagnostic relevance. *Transplant Proc* 2007;39:511-513.
158. Muller-Steinhardt M, Ebel B & Hartel C. The impact of interleukin-6 promoter -597/-572/-174 genotype on interleukin-6 production after lipopolysaccharide stimulation. *Clin Exp Immunol* 2007;147:339-345.
159. Dianzani F & Baron S. Nonspecific Defenses. In: *Medical Microbiology*. Ed. Baron S. Library of Congress Cataloging-in-Publication Data, 1996.
160. Hidalgo LG & Halloran PF. Role of IFN-gamma in allograft rejection. *Crit Rev Immunol* 2002;22:317-349.
161. Schenone M, Furie BC & Furie B. The blood coagulation cascade. *Curr Opin Hematol* 2004;11:272-277.



162. Racusen LC. Immunopathology of organ transplantation. Springer Semin Immunopathol 2003;25:141-165.
163. Yamazaki T, Nicolaes GA, Sorensen KW & Dahlback B. Molecular basis of quantitative factor V deficiency associated with factor V R2 haplotype. Blood 2002;100:2515-2521.
164. Alhenc-Gelas M, Nicaud V, Gandrille S, et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999;81:193-197.
165. Danckwardt S, Hartmann K, Gehring NH, Hentze MW & Kulozik AE. 3' end processing of the prothrombin mRNA in thrombophilia. Acta Haematol 2006;115:192-197.
166. Levo A, Kuismanen K, Holopainen P, et al. Single founder mutation (W380G) in type II protein C deficiency in Finland. Thromb Haemost 2000;84:424-428.
167. Kleesiek K, Schmidt M, Gotting C, et al. The 536C-->T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost 1999;82:1-5.
168. Wells PS, Anderson JL, Rodger MA, Carson N, Grimwood RL & Doucette SP. The factor XIII Val34Leu polymorphism: is it protective against idiopathic venous thromboembolism? Blood Coagul Fibrinolysis 2006;17:533-538.
169. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
170. Irish AB, Green FR, Gray DW & Morris PJ. The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients. Transplantation 1997;64:604-607.
171. Heidenreich S, Dercken C, August C, Koch HG & Nowak-Gottl U. High rate of acute rejections in renal allograft recipients with thrombophilic risk factors. J Am Soc Nephrol 1998;9:1309-1313.
172. Ekberg H, Svensson PJ, Simanaitis M & Dahlback B. Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection. Transplantation 2000;69:1577-1581.
173. Wuthrich RP, Cicvara-Muzar S, Booy C & Maly FE. Heterozygosity for the factor V Leiden (G1691A) mutation predisposes renal transplant recipients to thrombotic complications and graft loss. Transplantation 2001;72:549-550.
174. Hoher B, Slowinski T, Hauser I, et al. Association of factor V Leiden mutation with delayed graft function, acute rejection episodes and long-term graft dysfunction in kidney transplant recipients. Thromb Haemost 2002;87:194-198.
175. Heidenreich S, Junker R, Wolters H, et al. Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospective study. J Am Soc Nephrol 2003;14:234-239.
176. Irish AB & Green FR. Environmental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1997;12:167-173.

177. Fischereder M, Gohring P, Schneeberger H, et al. Early loss of renal transplants in patients with thrombophilia. *Transplantation* 1998;65:936-939.
178. Pherwani AD, Winter PC, McNamee PT, et al. Is screening for Factor V Leiden and prothrombin G20210A mutations in renal transplantation worthwhile? Results of a large single-center UK study. *Transplantation* 2003;76:603-605.
179. Pagano CR, Dawson L, Dick A, et al. No increase in rejection or graft loss in kidney transplant recipients with thrombophilia treated with anticoagulation and triple immunosuppression. *Transplant Proc* 2005;37:1902-1904.
180. Meyer M, Laux G, Scherer S, Tran TH, Opelz G & Mytilineos J. No Association of Factor V Leiden, Prothrombin G20210A, and MTHFR C677T Gene Polymorphisms With Kidney Allograft Survival: A Multicenter Study. *Transplantation* 2007;83:1055-1058.
181. Poort SR, Rosendaal FR, Reitsma PH & Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. *Blood* 1996;88:3698-3703.
182. Fischereder M, Schneeberger H, Lohse P, Kramer BK, Schlondorff D & Land W. Increased rate of renal transplant failure in patients with the G20210A mutation of the prothrombin gene. *Am J Kidney Dis* 2001;38:1061-1064.
183. Pereira AC, Miyakawa AA, Lopes NH, et al. Dynamic regulation of MTHFR mRNA expression and C677T genotype modulate mortality in coronary artery disease patients after revascularization. *Thromb Res* 2007;121:25-32.
184. Fodinger M, Wolfl G, Fischer G, et al. Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients. *Kidney Int* 1999;55:1072-1080.
185. Fodinger M, Buchmayer H, Heinz G, et al. Effect of MTHFR 1298A-->C and MTHFR 677C-->T genotypes on total homocysteine, folate, and vitamin B(12) plasma concentrations in kidney graft recipients. *J Am Soc Nephrol* 2000;11:1918-1925.
186. Bertoni E, Marcucci R, Zanazzi M, et al. Hyperhomocysteinemia in renal transplant patients: an independent factor of cardiovascular disease. *J Nephrol* 2001;14:36-42.
187. Cossu M, Carru C, Pes GM, et al. Plasma homocysteine levels and C677T MTHFR gene polymorphism in stable renal graft recipients. *Transplant Proc* 2001;33:1156-1158.
188. Marcucci R, Fedi S, Brunelli T, et al. High cysteine levels in renal transplant recipients: relationship with hyperhomocysteinemia and 5,10-MTHFR polymorphism. *Transplantation* 2001;71:746-751.
189. Szabo AJ, Tulassay T, Melegh B, et al. Hyperhomocysteinaemia and MTHFR C677T gene polymorphism in renal transplant recipients. *Arch Dis Child* 2001;85:47-49.
190. Yilmaz H, Agachan B, Isbir T & Akoglu E. Is there additional effect of MTHFR C677T mutation on lipid abnormalities in renal allograft recipients? *Transplant Proc* 2003;35:1390-1392.

191. Viklicky O, Hubacek JA, Kvasnicka J, et al. Association of methylenetetrahydrofolate reductase T677 allele with early development of chronic allograft nephropathy. *Clin Biochem* 2004;37:919-924.
192. Pavarino-Bertelli EC, Sanches de Alvarenga MP, Goloni-Bertollo EM, et al. Hyperhomocysteinemia and MTHFR C677T and A1298C polymorphisms are associated with chronic allograft nephropathy in renal transplant recipients. *Transplant Proc* 2004;36:2979-2981.
193. Liangos O, Kreutz R, Beige J, Offermann G, Distler A & Sharma AM. Methylenetetrahydrofolate-reductase gene C677T variant and kidney-transplant survival. *Nephrol Dial Transplant* 1998;13:2351-2354.
194. Hagen W, Fodinger M, Heinz G, Buchmayer H, Horl WH & Sunder-Plassmann G. Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. *Kidney Int Suppl* 2001;78:S253-S257.
195. Aldamiz-Echevarria L, Sanjurjo P, Vallo A, et al. Hyperhomocysteinemia in children with renal transplants. *Pediatr Nephrol* 2002;17:718-723.
196. Winkelmayer WC, Kramar R, Sunder-Plassmann G & Fodinger M. Effects of single-nucleotide polymorphisms in MTHFR and MTRR on mortality and allograft loss in kidney transplant recipients. *Kidney Int* 2005;68:2857-2862.
197. Mushiroda T, Saito S, Tanaka Y, et al. A model of prediction system for adverse cardiovascular reactions by calcineurin inhibitors among patients with renal transplants using gene-based single-nucleotide polymorphisms. *J Hum Genet* 2005;50:442-447.
198. Lachenbruch PA, Rosenberg AS, Bonvini E, Cavaille-Coll MW & Colvin RB. Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design. *Am J Transplant* 2004;4:451-457.
199. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. *Kidney Int* 1999;55:713-723.
200. Racusen LC. The Banff schema and differential diagnosis of allograft dysfunction. *Transplant Proc* 2004;36:753-754.
201. Biancone L, Segoloni G, Turello E, et al. Expression of inducible lymphocyte costimulatory molecules in human renal allograft. *Nephrol Dial Transplant* 1998;13:716-722.
202. Grimm PC, McKenna R, Nickerson P, et al. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. *J Am Soc Nephrol* 1999;10:1582-1589.
203. Park KK, Han SM, Jegal MY, Jeong HS, Lee JG & Kim HC. Patterns and sites of tumor necrosis factor-alpha and transforming growth factor-beta1 expression in human renal allograft biopsies. *Transplant Proc* 2003;35:249-250.
204. Striz I, Eliska K, Eva H, et al. Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft. *Immunol Lett* 2005;99:30-35.

205. Yin JL, Hambly BD, Bao SS, Painter D, Bishop GA & Eris JM. Expression of growth arrest-specific gene 6 and its receptors in dysfunctional human renal allografts. *Transpl Int* 2003;16:681-688.
206. Jain S, Mohamed MA, Sandford R, Furness PN, Nicholson ML & Talbot D. Sequential protocol biopsies from renal transplant recipients show an increasing expression of active TGF beta. *Transpl Int* 2002;15:630-634.
207. Sawada T, Abe M, Kai K, Kubota K, Fuchinoue S & Teraoka S. beta6 integrin is up-regulated in chronic renal allograft dysfunction. *Clin Transplant* 2004;18:525-528.
208. Veronese FV, Noronha IL, Manfro RC, Edelweiss MI, Goldberg J & Goncalves LF. Prevalence and immunohistochemical findings of subclinical kidney allograft rejection and its association with graft outcome. *Clin Transplant* 2004;18:357-364.
209. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). *Am J Transplant* 2007;7:518-526.
210. Pasternack A, Virolainen M & Häyry P. Fine-needle aspiration biopsy in the diagnosis of human renal allograft rejection. *J Urol* 1973;109:167-172.
211. Andersen CB. Acute kidney graft rejection morphology and immunology. *APMIS Suppl* 1997;67:1-35.
212. Their M, von Willebrand E, Taskinen E, Rönholm K, Holmberg C & Jalanko H. Fine-needle aspiration biopsy allows early detection of acute rejection in children after renal transplantation. *Transplantation* 2001;71:736-743.
213. Belitsky P & Gupta R. Fine-needle aspiration biopsy--new application for an old technique. *Transplantation* 2001;71:709-710.
214. Engvall E & Perlman P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. *Immunochemistry* 1971;8:871-874.
215. Susal C, Pelzl S, Simon T & Opelz G. Advances in pre- and posttransplant immunologic testing in kidney transplantation. *Transplant Proc* 2004;36:29-34.
216. Matinlauri IH, Kyllönen LE, Salmela KT, Helin H, Pelzl S & Susal C. Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations. *Transplantation* 2005;80:1809-1812.
217. Pelzl S, Opelz G, Daniel V, Wiesel M & Susal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. *Transplantation* 2003;75:421-423.
218. Rouschop KM, Roelofs JJ, Rowshani AT, et al. Pre-transplant plasma and cellular levels of CD44 correlate with acute renal allograft rejection. *Nephrol Dial Transplant* 2005;20:2248-2254.
219. Rouschop KM, Roelofs JJ, Sylva M, et al. Renal expression of CD44 correlates with acute renal allograft rejection. *Kidney Int* 2006;70:1127-1134.

220. Fitzgerald JT, Johnson JR & Perez RV. Pre-transplant elevations of interleukin-12 and interleukin-10 are associated with acute rejection after renal transplantation. *Clin Transplant* 2004;18:434-439.
221. Le Meur Y, Leprivey-Lorgeot V, Mons S, et al. Serum levels of macrophage-colony stimulating factor (M-CSF): a marker of kidney allograft rejection. *Nephrol Dial Transplant* 2004;19:1862-1865.
222. Granja C, Moliterno RA, Ferreira MS, Fonseca JA, Kalil J & Coelho V. T-cell autoreactivity to Hsp in human transplantation may involve both proinflammatory and regulatory functions. *Hum Immunol* 2004;65:124-134.
223. Sadeghi M, Daniel V, Weimer R, Wiesel M, Hergesell O & Opelz G. Pre-transplant Th1 and post-transplant Th2 cytokine patterns are associated with early acute rejection in renal transplant recipients. *Clin Transplant* 2003;17:151-157.
224. Delude RL. Flow cytometry. *Crit Care Med* 2005;33:S426-S428.
225. McKenna RM, Takemoto SK & Terasaki PI. Anti-HLA antibodies after solid organ transplantation. *Transplantation* 2000;69:319-326.
226. Pei R, Lee JH, Shih NJ, Chen M & Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. *Transplantation* 2003;75:43-49.
227. Mihaylova A, Baltadjieva D, Boneva P, et al. Clinical relevance of anti-HLA antibodies detected by flow-cytometry bead-based assays-single-center experience. *Hum Immunol* 2006;67:787-794.
228. Posselt AM, Vincenti F, Bedolli M, Lantz M, Roberts JP & Hirose R. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients. *Transplantation* 2003;76:190-195.
229. Shabtai M, Waltzer WC, Ayalon A, Shabtai EL & Malinowski K. Down regulation of CD45 expression on CD4 T cells during acute renal allograft rejection: evidence of a decline in T suppressor/inducer activity. *Int Urol Nephrol* 2002;34:555-558.
230. Zhang YG, Guan D, Xia CQ, et al. Relationship between the expression levels of CD61, CD63, and PAC-1 on platelet surface in peripheral blood and the transplanted kidney function. *Transplant Proc* 2003;35:1360-1363.
231. Barratt J & Topham P. Urine proteomics: the present and future of measuring urinary protein components in disease. *CMAJ* 2007;177:361-368.
232. Clarke W, Silverman BC, Zhang Z, Chan DW, Klein AS & Molmenti EP. Characterization of renal allograft rejection by urinary proteomic analysis. *Ann Surg* 2003;237:660-665.
233. Schaub S, Rush D, Wilkins J, et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. *J Am Soc Nephrol* 2004;15:219-227.
234. Wittke S, Haubitz M, Walden M, et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. *Am J Transplant* 2005;5:2479-2488.

235. Voshol H, Brendlen N, Muller D, et al. Evaluation of biomarker discovery approaches to detect protein biomarkers of acute renal allograft rejection. *J Proteome Res* 2005;4:1192-1199.
236. Reichelt O, Muller J, von Eggeling F, et al. Prediction of renal allograft rejection by urinary protein analysis using ProteinChip Arrays (surface-enhanced laser desorption/ionization time-of-flight mass spectrometry). *Urology* 2006;67:472-475.
237. O'Riordan E, Orlova TN, Mei JJ, et al. Bioinformatic analysis of the urine proteome of acute allograft rejection. *J Am Soc Nephrol* 2004;15:3240-3248.
238. O'Riordan E & Goligorsky MS. Emerging studies of the urinary proteome: the end of the beginning? *Curr Opin Nephrol Hypertens* 2005;14:579-585.
239. O'Riordan E, Orlova TN, Podust VN, et al. Characterization of urinary peptide biomarkers of acute rejection in renal allografts. *Am J Transplant* 2007;7:930-940.
240. Heid CA, Stevens J, Livak KJ & Williams PM. Real time quantitative PCR. *Genome Res* 1996;6:986-994.
241. Kubista M, Andrade JM, Bengtsson M, et al. The real-time polymerase chain reaction. *Mol Aspects Med* 2006;27:95-125.
242. Karlen Y, McNair A, Perseguers S, Mazza C & Mermoud N. Statistical significance of quantitative PCR. *BMC Bioinformatics* 2007;8:131.
243. Livak KJ & Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>(-Delta Delta C(T))</sup> Method. *Methods* 2001;25:402-408.
244. Schena M, Shalon D, Davis RW & Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. *Science* 1995;270:467-470.
245. Sarwal M, Chang S, Barry C, et al. Genomic analysis of renal allograft dysfunction using cDNA microarrays. *Transplant Proc* 2001;33:297-298.
246. Chua MS, Mansfield E & Sarwal M. Applications of microarrays to renal transplantation: progress and possibilities. *Front Biosci* 2003;8:s913-s923.
247. Mansfield E, Hernandez-Boussard T & Sarwal M. Arrays Amaze: Unraveling the Transcriptome in Transplantation. *ASHI Q* 2003;27:11-15.
248. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. *N Engl J Med* 2003;349:125-138.
249. Chua MS, Barry C, Chen X, Salvatierra O & Sarwal MM. Molecular profiling of anemia in acute renal allograft rejection using DNA microarrays. *Am J Transplant* 2003;3:17-22.
250. Chua MS & Sarwal MM. Microarrays: new tools for transplantation research. *Pediatr Nephrol* 2003;18:319-327.
251. Satterwhite T, Chua MS, Hsieh SC, et al. Increased expression of cytotoxic effector molecules: different interpretations for steroid-based and steroid-free immunosuppression. *Pediatr Transplant* 2003;7:53-58.

252. Mansfield ES & Sarwal MM. Arraying the orchestration of allograft pathology. *Am J Transplant* 2004;4:853-862.
253. Melk A, Mansfield ES, Hsieh SC, et al. Transcriptional analysis of the molecular basis of human kidney aging using cDNA microarray profiling. *Kidney Int* 2005;68:2667-2679.
254. Sarwal MM. Chipping into the human genome: novel insights for transplantation. *Immunol Rev* 2006;210:138-155.
255. Weintraub LA & Sarwal MM. Microarrays: a monitoring tool for transplant patients? *Transpl Int* 2006;19:775-788.
256. Sarwal MM & Li L. Designer genes: filling the gap in transplantation. *Transplantation* 2006;82:1261-1272.
257. Flechner SM, Kurian SM, Head SR, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. *Am J Transplant* 2004;4:1475-1489.
258. Morgun A, Shulzhenko N, Perez-Diez A, et al. Molecular profiling improves diagnoses of rejection and infection in transplanted organs. *Circ Res* 2006;98:e74-e83.
259. Scherer A, Krause A, Walker JR, Korn A, Niese D & Raulf F. Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. *Transplantation* 2003;75:1323-1330.
260. Park WD & Stegall MD. A meta-analysis of kidney microarray datasets: investigation of cytokine gene detection and correlation with rt-PCR and detection thresholds. *BMC Genomics* 2007;8:88.
261. Akalin E, Hendrix RC, Polavarapu RG, et al. Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology. *Transplantation* 2001;72:948-953.
262. Mueller TF, Einecke G, Reeve J, et al. Microarray Analysis of Rejection in Human Kidney Transplants Using Pathogenesis-Based Transcript Sets. *Am J Transplant* 2007;7:2712-2722.
263. Kurian SM, Flechner SM & Salomon DR. Genomics and proteomics in transplantation. *Curr Opin Organ Transplant* 2005;10:191-197.
264. Strehlau J, Pavlakis M, Lipman M, Maslinski W, Shapiro M & Strom TB. The intragraft gene activation of markers reflecting T-cell-activation and -cytotoxicity analyzed by quantitative RT-PCR in renal transplantation. *Clin Nephrol* 1996;46:30-33.
265. Strehlau J, Pavlakis M, Lipman M, et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. *Proc Natl Acad Sci U S A* 1997;94:695-700.
266. Vasconcellos LM, Schachter AD, Zheng XX, et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. *Transplantation* 1998;66:562-566.
267. Hoffmann SC, Pearl JP, Blair PJ & Kirk AD. Immune profiling: molecular monitoring in renal transplantation. *Front Biosci* 2003;8:e444-e462.
268. Hoffmann SC, Hale DA, Kleiner DE, et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. *Am J Transplant* 2005;5:573-581.



269. Carstens J, Markussen N & Madsen M. The granule exocytosis and Fas/FasLigand pathways at the time of transplantation and during borderline and acute rejection of human renal allografts. *Transplant Proc* 2005;37:3294-3297.
270. Graziotto R, Del Prete D, Rigotti P, et al. Perforin, Granzyme B, and Fas Ligand for Molecular Diagnosis of Acute Renal-Allograft Rejection: Analyses on Serial Biopsies Suggest Methodological Issues. *Transplantation* 2006;81:1125-1132.
271. Nickel P, Lacha J, Ode-Hakim S, et al. Cytotoxic effector molecule gene expression in acute renal allograft rejection: correlation with clinical outcome; histopathology and function of the allograft. *Transplantation* 2001;72:1158-1160.
272. Dias ECA, Veronese FJ, Santos Goncalves LF & Manfro RC. Molecular markers in subclinical acute rejection of renal transplants. *Clin Transplant* 2004;18:281-287.
273. Desvaux D, Schwarzwinger M, Pastural M, et al. Molecular Diagnosis of Renal-Allograft Rejection: Correlation with Histopathologic Evaluation and Antirejection-Therapy Resistance. *Transplantation* 2004;78:647-653.
274. Suthanthiran M. Immunologic monitoring: implications for treatment of rejection. *Transplant Proc* 2000;32:1493-1494.
275. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. *N Engl J Med* 2001;344:947-954.
276. Muthukumar T, Ding R, Dadhania D, et al. Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. *Transplantation* 2003;75:1565-1570.
277. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. *N Engl J Med* 2005;353:2342-2351.
278. Yannaraki M, Rebibou JM, Ducloux D, et al. Urinary cytotoxic molecular markers for a noninvasive diagnosis in acute renal transplant rejection. *Transpl Int* 2006;19:759-768.
279. Galante NZ, Camara NO, Kallas EG, Salomao R, Pacheco-Silva A & Medina-Pestana JO. Noninvasive immune monitoring assessed by flow cytometry and real time RT-PCR in urine of renal transplantation recipients. *Transpl Immunol* 2006;16:73-80.
280. Kotsch K, Mashreghi MF, Bold G, et al. Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. *Transplantation* 2004;77:1866-1875.
281. Dadhania D, Muthukumar T, Ding R, et al. Molecular signatures of urinary cells distinguish acute rejection of renal allografts from urinary tract infection. *Transplantation* 2003;75:1752-1754.
282. Dugre FJ, Gaudreau S, Belles-Isles M, Houde I & Roy R. Cytokine and cytotoxic molecule gene expression determined in peripheral blood mononuclear cells in the diagnosis of acute renal rejection. *Transplantation* 2000;70:1074-1080.



283. Simon T, Opelz G, Wiesel M, Ott RC & Susal C. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. *Am J Transplant* 2003;3:1121-1127.
284. Simon T, Opelz G, Wiesel M, Pelzl S, Ott RC & Susal C. Serial peripheral blood interleukin-18 and perforin gene expression measurements for prediction of acute kidney graft rejection. *Transplantation* 2004;77:1589-1595.
285. Shin GT, Kim SJ, Lee TS, Oh CK & Kim H. Gene expression of perforin by peripheral blood lymphocytes as a marker of acute rejection. *Nephron Clin Pract* 2005;100:c63-c70.
286. Veale JL, Liang LW, Zhang Q, et al. Noninvasive diagnosis of cellular and antibody-mediated rejection by perforin and granzyme B in renal allografts. *Hum Immunol* 2006;67:777-786.
287. Zhou PJ, Tang XD, Wang XH & Xu D. Immune activation gene expression in CD28 costimulated lymphocytes and its application as a diagnostic tool in kidney transplantation. *Transplant Proc* 2000;32:1774-1776.
288. Sabek O, Dorak MT, Kotb M, Gaber AO & Gaber L. Quantitative detection of T-cell activation markers by real-time PCR in renal transplant rejection and correlation with histopathologic evaluation. *Transplantation* 2002;74:701-707.
289. Alakulppi NS, Kyllönen LE, Partanen J, Salmela KT & Laine JT. Diagnosis of acute renal allograft rejection by analyzing whole blood mRNA expression of lymphocyte marker molecules. *Transplantation* 2007;83:791-798.
290. Sarwal MM, Jani A, Chang S, et al. Granulysin expression is a marker for acute rejection and steroid resistance in human renal transplantation. *Hum Immunol* 2001;62:21-31.
291. Shoker A, George D, Yang H & Baltzan M. Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection. *Transplantation* 2000;70:497-505.
292. Leushner J & Chiu NH. Automated mass spectrometry: a revolutionary technology for clinical diagnostics. *Mol Diagn* 2000;5:341-348.
293. Purcell S, Cherny SS & Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics* 2003;19:149-150.
294. Gourley IS, Denofrio D, Rand W, Desai S, Loh E & Kamoun M. The effect of recipient cytokine gene polymorphism on cardiac transplantation outcome. *Hum Immunol* 2004;65:248-254.
295. Heidenreich S, Lang D, Tepel M & Rahn KH. Monocyte activation for enhanced tumour necrosis factor-alpha and interleukin 6 production during chronic renal allograft rejection. *Transpl Immunol* 1994;2:35-40.
296. McLaughlin PJ, Aikawa A, Davies HM, et al. Evaluation of sequential plasma and urinary tumor necrosis factor alpha levels in renal allograft recipients. *Transplantation* 1991;51:1225-1229.
297. Gaudet MM, Egan KM, Lissowska J, et al. Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk. *Hum Genet* 2007;121:483-490.

298. Bayley JP, de Rooij H, van den Elsen PJ, Huizinga TW & Verweij CL. Functional analysis of linker-scan mutants spanning the -376, -308, -244, and -238 polymorphic sites of the TNF-alpha promoter. *Cytokine* 2001;14:316-323.
299. Bayley JP, Ottenhoff TH & Verweij CL. Is there a future for TNF promoter polymorphisms? *Genes Immun* 2004;5:315-329.
300. Awad MR, Webber S, Boyle G, et al. The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. *J Heart Lung Transplant* 2001;20:625-630.
301. Turner D, Grant SC, Yonan N, et al. Cytokine gene polymorphism and heart transplant rejection. *Transplantation* 1997;64:776-779.
302. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB & Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. *J Exp Med* 1993;177:557-560.
303. Asano H, Kobayashi T, Uchida K, et al. Significance of tumor necrosis factor microsatellite polymorphism in renal transplantation. *Tissue Antigens* 1997;50:484-488.
304. Candore G, Lio D, Colonna RG & Caruso C. Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. *Autoimmun Rev* 2002;1:29-35.
305. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ & Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. *Eur J Immunogenet* 1997;24:1-8.
306. Varilo T & Peltonen L. Isolates and their potential use in complex gene mapping efforts. *Curr Opin Genet Dev* 2004;14:316-323.
307. Alakulppi NS, Kyllönen LE, Salo HM, Partanen J, Salmela KT & Laine JT. The impact of donor cytokine gene polymorphisms on the incidence of cytomegalovirus infection after kidney transplantation. *Transpl Immunol* 2006;16:258-262.
308. Perrey C, Pravica V, Sinnott PJ & Hutchinson IV. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. *Transpl Immunol* 1998;6:193-197.
309. Conti P, Kempuraj D, Kandere K, et al. IL-10, an inflammatory/inhibitory cytokine, but not always. *Immunol Lett* 2003;86:123-129.
310. Spencer JV, Lockridge KM, Barry PA, et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. *J Virol* 2002;76:1285-1292.
311. Kotenko SV, Sacconi S, Izotova LS, Mirochnitchenko OV & Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). *Proc Natl Acad Sci U S A* 2000;97:1695-1700.
312. Geist LJ & Hinde SL. Susceptibility to cytomegalovirus infection may be dependent on the cytokine response to the virus. *J Investig Med* 2001;49:434-441.
313. Hariharan S. Case 5: new clinical trials in renal transplantation. *Transplantation* 2003;76:1270-1274.
314. Sola R, Alarcon A, Jimenez C & Osuna A. The influence of delayed graft function. *Nephrol Dial Transplant* 2004;19 Suppl 3:iii32-iii37.

315. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. *Lancet* 2005;365:2105-2115.
316. Rosendorff A & Dorfman DM. Activated protein C resistance and factor V Leiden: a review. *Arch Pathol Lab Med* 2007;131:866-871.
317. den Heijer M, Lewington S & Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. *J Thromb Haemost* 2005;3:292-299.
318. Kelberman D, Hawe E, Luong LA, et al. Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. The HIFMECH Study. *Thromb Haemost* 2004;92:1122-1128.
319. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. *N Engl J Med* 2002;347:1916-1923.
320. Doggen CJ, DE Visser MC, Vos HL, Bertina RM, Cats VM & Rosendaal FR. The HR2 haplotype of factor V is not associated with the risk of myocardial infarction. *Thromb Haemost* 2000;84:815-818.
321. Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H & Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. *Thromb Haemost* 1998;79:8-13.
322. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. *Nat Genet* 2002;32:650-654.
323. Kimura A, Takahashi M, Choi BY, et al. Lack of association between LTA and LGALS2 polymorphisms and myocardial infarction in Japanese and Korean populations. *Tissue Antigens* 2007;69:265-269.
324. Gorroochurn P, Hodge SE, Heiman GA, Durner M & Greenberg DA. Non-replication of association studies: "pseudo-failures" to replicate? *Genet Med* 2007;9:325-331.
325. Casas JP, Bautista LE, Smeeth L, Sharma P & Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. *Lancet* 2005;365:224-232.
326. Sahoo S, Kang S, Supran S, Saloman R, Wolfe H & Freeman RB. Tumor necrosis factor genetic polymorphisms correlate with infections after renal transplantation. *Transplantation* 2000;69:880-884.
327. Gwinner W. Renal transplant rejection markers. *World J Urol* 2007;
328. Nemlander A, Soots A, von Willebrand E, Husberg B & Hayry P. Redistribution of renal allograft-responding leukocytes during rejection. II. Kinetics and specificity. *J Exp Med* 1982;156:1087-1100.
329. Zheng XX, Schachter AD, Vasconcellos L, et al. Increased CD40 ligand gene expression during human renal and murine islet allograft rejection. *Transplantation* 1998;65:1512-1515.
330. Souillou JP. Immune monitoring for rejection of kidney transplants. *N Engl J Med* 2001;344:1006-1007.

331. McLean A. What Goes Around (in Kidney Transplant Rejection) Does Not Necessarily Come Around (in the Blood). *Am J Transplant* 2003;3:1045-1046.
332. Halloran PF, Reeve J & Kaplan B. Lies, damn lies, and statistics: the perils of the P value. *Am J Transplant* 2006;6:10-11.
333. Hartono C, Dadhania D & Suthanthiran M. Noninvasive diagnosis of acute rejection of solid organ transplants. *Front Biosci* 2004;9:145-153.
334. Stordeur P, Zhou L, Byl B, et al. Immune monitoring in whole blood using real-time PCR. *J Immunol Methods* 2003;276:69-77.
335. Thach DC, Lin B, Walter E, et al. Assessment of two methods for handling blood in collection tubes with RNA stabilizing agent for surveillance of gene expression profiles with high density microarrays. *J Immunol Methods* 2003;283:269-279.
336. Rainen L, Oelmueller U, Jurgensen S, et al. Stabilization of mRNA expression in whole blood samples. *Clin Chem* 2002;48:1883-1890.
337. Feezor RJ, Baker HV, Mindrinos M, et al. Whole blood and leukocyte RNA isolation for gene expression analyses. *Physiol Genomics* 2004;19:247-254.
338. Alvarez CM, Paris SC, Arango L, Arbelaez M & Garcia LF. Kidney transplant patients with long-term graft survival have altered expression of molecules associated with T-cell activation. *Transplantation* 2004;78:1541-1547.
339. Liu J, Walter E, Stenger D & Thach D. Effects of globin mRNA reduction methods on gene expression profiles from whole blood. *J Mol Diagn* 2006;8:551-558.
340. Horwitz PA, Tsai EJ, Putt ME, et al. Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. *Circulation*.
341. Schiff J, Cole E & Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. *Clin J Am Soc Nephrol* 2007;2:374-384.
342. Pacheco-Silva A. Immune function, as assessed by the ImmuKnow assay, correlates with clinical outcomes in transplant recipients. *Nat Clin Pract Nephrol* 2007;3:196-197.
343. Schaub S, Wilkins JA, Rush D & Nickerson P. Developing a tool for noninvasive monitoring of renal allografts. *Expert Rev Proteomics* 2006;3:497-509.
344. Khoury MJ, Little J, Gwinn M & Ioannidis JP. On the synthesis and interpretation of consistent but weak gene-disease associations in the era of genome-wide association studies. *Int J Epidemiol* 2007;36:439-445.

## **ORIGINAL PUBLICATIONS**

## ACADEMIC DISSERTATIONS FROM THE FINNISH RED CROSS BLOOD SERVICE

- 1. Nevanlinna, H.R.** Factors affecting maternal Rh immunisation. Helsinki 1953
- 2. Ikkala, Eero.** Haemophilia. A study of its laboratory, clinical, genetic and social aspects based on known haemophiliacs in Finland. Helsinki 1960.
- 3. Vuopio, Pekka.** Red Cell enzymes in anemia. Helsinki 1963.
- 4. Pyörälä, Kalevi.** Determinants of the clotting factor response to warfarin in the rat. Helsinki 1965.
- 5. Häyry, Pekka.** The role of factors in fresh serum in the attachment and growth of HeLA cells on glass. Helsinki 1966.
- 6. Kotilainen, Martti.** Platelet kinetics in normal subjects and in haematological disorders. Helsinki 1969.
- 7. Myllylä, Gunnar.** Aggregation of human blood platelets by immune complexes in the sedimentation pattern test. Helsinki 1973.
- 8. Helske, Timo.** Carriers of hepatitis B antigen and transfusion hepatitis in Finland. Helsinki 1974.
- 9. Jalonen, Kari.** Genetic control of coumarin anticoagulant metabolism in the rat. Helsinki 1974.
- 10. Koistinen, Jukka.** Studies of selective deficiency of serum IgA and its significance in blood transfusion. Helsinki 1975.
- 11. Suomela, Hannu.** Human blood coagulation factor IX. Preparation of a factor IX concentrate for therapeutic use; the purification, characterization and function of factor IX. Helsinki 1977.
- 12. Eklund, Jarl.** Prevention of Rh immunization in Finland. A national study, 1969 - 1977. Helsinki 1978.
- 13. Kaakinen, Aulikki.** Identification, genetics and significance of the HLA-D determinants. Tampere 1978.
- 14. Ukkonen, Pentti.** Hepatitis B surface antigen subtypes and e antigen. Methodological and epidemiological studies. Helsinki 1978.
- 15. Kekomäki, Riitta.** The detection of platelet-reactive IgG. The use of human blood platelets and radio labelled staphylococcal protein A. Helsinki 1979.
- 16. Linko, Kai.** Warming of stored blood for massive transfusions. Helsinki 1979.
- 17. Himberg, Jaakko-Juhani.** Optimization and validation of gas chromatographic drug assays for pharmacokinetic studies. A model study with four benzodiazepines. Helsinki 1982.
- 18. Rasi, Vesa.** Plasma  $\beta$ -thromboglobulin. Methodological and clinical studies. Helsinki 1982.
- 19. Verkasalo, Matti.** Tissue antigens and clinical risk factors in intestinal cow's milk allergy and coeliac disease in children. Helsinki 1982.
- 20. Sistonen, Pertti.** The LW (Landsteiner-Wiener) blood group system. Elucidation of the genetics of the LW blood group based on the finding of a "new" blood group antigen. Helsinki 1984.
- 21. Syrjälä, Martti.** <sup>111</sup>In-granulocyte scintigraphy. Methodological and clinical studies. Helsinki 1987.
- 22. Partanen, Jukka.** Genetic polymorphism of human HLA-linked complement C4 genes. Helsinki 1987.
- 23. Petäjä, Jari.** Fibrinolysis and venous thrombosis. Physiological and pathophysiological studies. Helsinki 1989.
- 24. Ebeling, Freja.** Post-transfusion hepatitis in Finland. Helsinki 1991.
- 25. Lokki, Marja-Liisa.** Immunogenetic studies of MHC complement BF and C4 alleles. Helsinki 1991.
- 26. Nieminen, Urpo.** Immune thrombocytopenic purpura. Serological and clinical studies in patients with idiopathic, drug-induced and post-vaccination thrombocytopenia. Helsinki 1992.
- 27. Laitinen, Tarja.** Major histocompatibility complex and recurrent spontaneous abortions. Helsinki 1993.
- 28. Koistinen, Vesa.** The alternative pathway of complement. Studies on

interactions of C3b with ligands, with special emphasis on factor H. Helsinki 1993.

**29. Kuitunen, Anne.** Hemostasis after cardiopulmonary bypass. Helsinki 1993.

**30. Jouhikainen, Taneli.** Lupus anticoagulant. Detection and clinical significance. Helsinki 1993.

**31. Kolho, Elina.** Hepatitis C virus antibodies in Finnish blood donors. Helsinki 1994.

**32. Oksanen, Kalevi.** Leukocyte depleted blood components in hematologic malignancies. Helsinki 1994.

**33. Tiirikainen, Maarit.** Detection of intracellular antigens by flow cytometry. Evaluation of a new permeabilization method for the detection of intracellular antigens in hematological malignancies. Helsinki 1995.

**34. Westman, Pia.** MHC genetics of HLA-B27-positive patients with ankylosing spondylitis or reactive arthritis. Studies of six gene loci centromeric to HLA-B. Helsinki 1996.

**35. Koskinen, Sinikka.** Primary selective IgA deficiency in healthy blood donors. A follow-up study of 20 years. Helsinki 1996.

**36. Hiippala, Seppo.** Replacement of surgical blood loss with colloids and plasma-poor red cells with special reference to plasma colloid osmotic pressure and hemostatic factors. Helsinki 1996.

**37. Polvi, Anne.** Genetic susceptibility to celiac disease: Major histocompatibility complex genes in celiac disease and in its animal model. Helsinki 1998.

**38. Levo, Antti.** From mutations to migrations. A genetic and genealogic study of steroid 21-hydroxylase (CYP21) deficiency in Finland. Helsinki 1998.

**39. Sirén, Marja-Kaisa.** Predisposing HLA alleles in congenital heart block. Immunogenetic studies. Helsinki 1998.

**40. Koskela, Satu.** Genetics of the platelet glycoprotein Ib/IX/V complex in families with Bernard-Soulier syndrome and in the normal population of Finland. Helsinki 1999.

**41. Kekomäki, Satu.** Clinical significance of platelet alloantigens. Helsinki 1999.

**42. Sainio, Susanna.** Immune thrombocytopenia in pregnancy. Helsinki 2000.

**43. Joutsu-Korhonen, Lotta.** Autoimmune thrombocytopenia. Detection of platelet associated IgG, reticulated platelets and platelet Fcγ receptor polymorphism in thrombocytopenic patients. Helsinki 2000.

**44. Capraro, Leena.** Transfusion practices in elective surgical procedures in Finnish hospitals. Helsinki 2001.

**45. Holopainen, Päivi.** Genetic susceptibility to celiac disease: HLA unlinked candidate genes. Helsinki 2002.

**46. Jaatinen, Taina.** Genetic Studies of the Human Complement C4 Region in MHC Class III. Helsinki 2002.

**47. Karell, Kati.** Dissecting genetic susceptibility to gluten sensitivity: HLA linked risk factors in coeliac disease and dermatitis herpetiformis. Helsinki 2003.

**48. von Bonsdorff, Leni.** A pharmaceutical human apotransferrin product for iron binding therapy. Helsinki 2003.

**49. Aroviita, Pekka.** Cord blood haematopoietic stem cell units for transplantation. Helsinki 2005.

**50. Javela, Kaija.** Laboratory analyses for evaluation of platelet disorders and platelet concentrates. Helsinki 2006.